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Abstract 
Influenza is a highly contagious, acute respiratory illness, which represents 
one of the main plagues worldwide. Even though some antiviral drugs are 
available, the alarming increase of virus strains resistant to them, highlights the 
need to find new antiviral compounds. The high mutation rate of the RNA 
genome of the influenza virus, combined with assortment of its multiple 
genomic segments, promotes antigenic diversity and new subtypes, allowing the 
virus to evade vaccines and become resistant to antiviral drugs. Thus, there is a 
continuing need for new anti-influenza therapy using novel targets and creative 
strategies.  
On the basis of the above considerations, an ideal target for therapy should 
be a viral component, whose function is essential for virus infection.  
In this contest, the influenza A virus hemagglutinin (HA) represents a very 
promising target. 
 
Keywords: Influenza, virus, drug, resistance, therapy, hemagglutinin. 
 
Abbreviations 
IAVs, Influenza A virus; ORFs, open reading frames, HA, hemagglutinin; 
NA, neuraminidase; M2, matrix 2; M1, matrix 1; NEP, nuclear export 
protein; NS2, nonstructural protein 2; RNP, ribonucleoprotein; NP, 
nucleoprotein; HEF, hemagglutinin-esterase-fusion protein; NLSs, nuclear 
localization signals; cRNA, complementary RNA; NAIs, neuraminidase 
inhibitors; DANA, 2-deoxy-2,3-didehydro- N-acetyl neuraminic acid; 
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1.1. Introduction  
 
Influenza is a contagious respiratory infection and it is considered to be one 
of the life-threatening infectious diseases.[1] It is a viral infection, associated 
with seasonal outbreaks of respiratory illness during the winter months in 
regions with temperate climates and during rainy seasons in tropical regions.  
In some countries seasonal influenza affects annually up to 40% of the 
population and 500 million people die from it worldwide every year.[2-4] 
The reasons for seasonal epidemics of influenza are not definitely known. 
They probably involve a combination of environmental factors such as low 
humidity and low temperature and social behaviors that facilitate person-to-
person transmission of influenza virus. At unpredictable intervals, influenza 
pandemics occur with very high attack rates and severe disease. In the 
population, influenza follows the general pattern that now appears to 
characterize essentially all respiratory infections. It can be particularly 
hazardous to individuals with poor immunity such as children and the elderly, 
and those with pulmonary, cardiovascular or other complications. Because of a 
lack of prior immunity, humans can be highly susceptible to infection and 
disease from these subtypes.  
Influenza in otherwise healthy persons is characterized predominantly by 
fever, myalgias, cough and other respiratory symptoms, and malaise. In most 
persons, recovery from these symptoms occurs in 5 to 7 days, but even in 
healthy persons symptoms of fatigue and malaise may not completely resolve 
for several weeks.  
Influenza may cause more severe pulmonary symptoms through direct 
invasion of the lung (leading to primary viral pneumonia) or by altering lung 
defense mechanisms in a variety of ways that lead to bacterial superinfection. 
This superinfection, which may occur simultaneously with influenza or follow 
it by days to weeks, may be responsible for much of the disease burden 
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associated with influenza. Although the primary target and clinically relevant 
tissue in influenza virus infection is the respiratory epithelium,[2] facultative 
infection of other organs, such as the cardiac or skeletal muscle, is possible and 
has occasionally been documented in cell culture and experimental animal 
infections.[5-9] 
 
1.2 Influenza viruses 
 
Influenza viruses, belonging to the Orthomyxoviridae family, are 
enveloped negative-strand RNA viruses with segmented genomes containing 
seven to eight gene segments.[4] 
One genus includes influenza A and B viruses, and the other comprises 
influenza C viruses. The three virus types differ in host range and pathogenicity. 
[10] Type B and C influenza viruses are isolated almost exclusively from humans, 
although influenza B viruses have been isolated from seals and influenza C 
viruses have been isolated from pigs and dogs.[11-12] 
Influenza A viruses, however, infect a wide variety of warm-blooded 
animals, including birds, swine, horses, humans, and other mammals. Influenza 
A and B viruses have a similar structure, whereas influenza C is more divergent. 
Influenza A- and B-type viruses contain eight discrete single-stranded RNA 
gene segments, each encoding at least one protein. Only Influenza A virus 
(IAVs) pose a significant risk of zoonotic infection, host switch, and the 
generation of pandemic IAVs. IAVs are enveloped with a host cell-derived lipid 
membrane. The eight gene segments encode at least 11 open reading frames 
(ORFs) (Figure 1.1).  
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Figure 1.1 Diagrammatic representation of an Influenza A Virus, the two major surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), along with small numbers 
of the matrix 2 (M2) ion channel protein, are embedded in a lipid bilayer (according 
to Ludwig et al. 2003). Adapted from “Antiviral agents targeting the influenza virus: a 
review and publication analysis,” by L. Eyer and K. Hruska, 2013, Veterinarni 
Medicina, 58, 113-185. 
 
The envelope bilayer harbors the two spike glycoproteins, hemagglutinin 
(HA) and neuraminidase (NA), and the M2 proton channel. HA is a glycosylated 
type I integral membrane protein with functions both as the viral receptor-
binding protein and fusion protein. NA cleaves glycosidic bonds with terminal 
SA facilitating the release of budding virions from the cell. There are 16 known 
HA (H1 to H16) and 9 NA (N1 to N9) subtypes in influenza A,[4, 13] leading to 
the current HxNy nomenclature. Routine human infections of seasonal influenza 
are mainly due to H1N1, H1N2 and influenza B; however, H3N2 is gradually 
becoming more abundant.[14] The small protein M2 is a proton channel 
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1.2.1 Virion structure and organization 
 
Influenza A and B viruses are virtually indistinguishable by electron 
microscopy. They are spherical or filamentous in shape, with the spherical 
forms on the order of 100 nm in diameter and the filamentous forms often in 
excess of 300 nm in length. The influenza A virion is studded with glycoprotein 
spikes of HA and NA, in a ratio of approximately four to one, projecting from 
a host cell–derived lipid membrane.[4] 
A smaller number of matrix ion channels (M2) traverse the lipid envelope, 
with an M2:HA ratio on the order of one M2 channel per 101-102 HA 
molecules.[15] The envelope and its three integral membrane proteins HA, NA, 
and M2 overlay a matrix of M1 protein, which encloses the virion core. Internal 
to the M1 matrix are found the nuclear export protein (NEP; also called 
nonstructural protein 2, NS2) and the ribonucleoprotein (RNP) complex, which 
consists of the viral RNA segments coated with nucleoprotein (NP) and the 
heterotrimeric RNAdependent RNA polymerase, composed of two “polymerase 
basic” and one “polymerase acidic” subunits (PB1, PB2, and PA). The 
organization of the influenza B virion is similar, with four envelope proteins: 
HA, NA, and, instead of M2, NB and BM2. Influenza C virions are structurally 
distinct from those of the A and B viruses; on infected cell surfaces, they can 
form long cordlike structures on the order of 500 μm. However, influenza C 
virions are compositionally similar, with a glycoprotein-studded lipid envelope 
overlying a protein matrix and the RNP complex. The influenza C viruses have 
only one major surface glycoprotein, the hemagglutinin-esterase-fusion (HEF) 
protein, which corresponds functionally to the HA and NA of influenza A and 
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1.2.2 The influenza virus replication cycle 
 
1.2.2.1 Virus attachment 
Influenza viruses recognize N-acetylneuraminic (sialic) acid on the host cell 
surface. Sialic acids are nine-carbon acidic monosaccharides commonly found 
at the termini of many glycoconjugates. The sialic acid moiety is recognized and 
bound by the HA spikes on the surface of influenza viruses.[16] 
 
 
Figure 1.2 Cellular targets for anti-influenza drugs in the context of the replication 
cycle of influenza virus. Stages of influenza A virus replication are in green. Cellular 
pathways shown by siRNA screens to be essential for completion of the viral replication 
cycle are shown in red. Adapted from “Cellular targets for influenza drugs,” by J. Min 
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1.2.2.2 Virus Entry 
Following attachment of the influenza virus HA to sialic acid, the virus is 
endocytosed. The acidity of the endosomal compartment is crucial to influenza 
virus uncoating in two ways. First, low pH triggers a conformational change in 
the HA, exposing a fusion peptide that mediates the merging of the viral 
envelope with the endosomal membrane, thus opening a pore through which the 
viral RNP’s are released into the host cell cytoplasm.[17, 18] Second, hydrogen 
ions from the endosome are pumped into the virus particle via the M2 ion 
channel. The M2 protein, a transmembrane ion channel found only in influenza 
A virus, has portions external to the viral envelope, along with the HA and 
NA.[19, 20] Internal acidification of the influenza virion via the M2 channel 
disrupts internal protein-protein interactions, allowing viral RNPs to be released 
from the viral matrix into the cellular cytoplasm.[21] 
 
1.2.2.3 Synthesis of Viral RNA 
Once liberated from the virion, RNPs are trafficked to the host cell nucleus 
by means of viral proteins’ nuclear localization signals (NLSs), which direct 
cellular proteins to import the RNPs and other viral proteins into the host cell 
nucleus.[22] The nucleus is the location of all influenza virus RNA synthesis. The 
viral RNAdependent RNA polymerase – a component of the RNPs imported 
into the nucleus – uses the negative-sense vRNA as a template to synthesize two 
positive-sense RNA species: mRNA templates for viral protein synthesis, and 
complementary RNA (cRNA) intermediates from which the RNA polymerase 
subsequently transcribes more copies of negative-sense, genomic vRNA. 
Nuclear export of vRNA segments, however, is mediated by the viral proteins 
M1 and NEP/NS2.[22] M1 interacts with both vRNA and NP and it also 
associates with the nuclear export protein NEP, which mediates the M1-RNP 
export via nucleoporins into the cytoplasm. 
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1.2.2.4 Virus Budding and Release 
Influenza virus budding occurs at the cell membrane, probably initiated by 
an accumulation of M1 matrix protein at the cytoplasmic side of the lipid 
bilayer. When budding is complete, HA spikes continue to bind the virions to 
the sialic acid on the cell surface until virus particles are actively released by the 
sialidase activity of the NA protein. The NA is a mushroom-shaped tetramer, 
anchored to the viral envelope by a transmembrane domain.[23, 24] It possesses 
receptor destroying activity, cleaving terminal sialic acid residues from cell-
surface glycoproteins and gangliosides to release progeny virus from the host 
cell. In viruses with inactive or absent NA, or in the presence of neuraminidase 
inhibitors, virus particles clump at the cell surface and infectivity is 
consequently reduced. The NA also removes sialic acid residues from the virus 
envelope itself, which prevents viral particle aggregation to enhance 
infectivity.[25, 26] The NA is also thought to aid virus infectivity by breaking 
down the mucins in respiratory tract secretions and allowing the virus to 
penetrate through to the respiratory epithelium, and it may play a role in virus 
entry into respiratory epithelial cells.[27] Host antibodies to the NA, as well as 
neuraminidase inhibitors, prevent virus release from infected cells and thus 
inhibit viral replication. 
 




The vaccination represent the main strategy for preventing infections. 
However, the vaccines are not able to follow the rapid virus antigenic drift, so 
that vaccine antigen composition needs to be updated annually based on global 
influenza surveillance. Efforts to influenza prevention by vaccination are made 
difficult by the virus ability to rapidly mutate and recombine into antigenically 
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new viral particles, sometimes leading to the emergence of a totally new virus. 
For this reason, at present, the development of antiviral drugs represents a 
crucial strategy in the control and prevention of seasonal and pandemic 
influenza infections.[28] Antiviral drugs can overcome the limitations of 
vaccination strategies, such as the time-consuming vaccine design, insufficient 
protection for immunocompromised patients and the unpredictable antigenic 
changes in influenza strains which render vaccination ineffective.  
The anti-influenza drugs are usually classified according to their target in the 
viral life-cycle, which is schematically depicted in Figure 1.2. Antiviral 
molecules are particularly used as inhibitors of the following processes: 
attachment of the virus to host cell receptors, endocytosis and fusion of viral 
and cell membranes, replication and transcription of the viral genome, synthesis 
of viral proteins, assembly of the viral progeny and release of the new virions 
into the outside environment. Two classes of antiviral drugs, the adamantane 
derivatives (amantadine and rimantadine) and neuraminidase inhibitors (NAIs; 
zanamivir and oseltamivir), have been approved for treatment and prophylaxis 
of influenza.[4, 29, 30] 
 
1.3.2 M2 ion channel blockers 
 
M2 ion channel is a transmembrane viral protein (Figure 1.1) that mediates 
the selective transport of protons into the interior of the influenza virion. 
Conductance of protons acidifies the internal space of the viral particle and 
facilitates the haemagglutinin-mediated membrane fusion, which in turn results 
in the uncoating of the influenza nucleocapsid and import of the viral genome 
into the nucleus.[31] Adamantanes are potent M2 channel blockers, which are 
known as the first synthetic anti-influenza drugs described in the mid-1960s.[32] 
Two adamantane derivatives, amantadine and rimantadine (Figure 1.3), have 
been licensed for influenza control and are commercially available under the 
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trademarks Symmetrel® and Flumadine®, respectively.[33] The adamantanes 
are relatively cheap, highly stable in storage and show strong anti-influenza 
activity at micromolar concentrations. At present, the application of 
adamantanes for prevention and treatment of influenza infections is, however, 
not recommended because of the rapid emergence of drug-resistant virus 
variants that retain full virulence and transmissibility.[34, 35] 
 
 
Figure 1.3 Structure of M2 ion channel inhibitors:  
amantadine (1) and rimantadine (2). 
 
1.3.3 Inhibitors of neuraminidase 
 
Neuraminidase, also referred to as sialidase, is an antigenic glycoprotein 
anchored in the surface envelope of the influenza virions, which hydrolytically 
cleaves the terminal sialic acid from the host cell receptors (Figure 1.2). Thus, 
it plays a crucial role in the release of viral progeny from the membranes of 
infected cells, prevents self-aggregation of virions and facilitates the movement 
of the infectious viral particles in the mucus of the respiratory epithelia.[27, 36] 
Influenza neuraminidase has been established as a key drug target for the 
prophylaxis and treatment of influenza infections, predominantly for the 
following reasons: firstly, the structure of the influenza neuraminidase active 
site is highly conserved between influenza A and B strains, making 
neuraminidase an attractive target for the development of broad-spectrum 
inhibitors.[37] Secondly, resistance to neuraminidase inhibitors develops less 
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commonly than to other anti-influenza drugs. Nevertheless, the intensive 
application of neuraminidase inhibitors for influenza treatment results in a 
permanently increasing number of drug-resistant strains.[38] Thirdly, in contrast 
to adamantanes, neuraminidase inhibitors are mostly well tolerated in patients 
under therapy.[39] Finally, neuraminidase protein is a freely accessible target for 
antiviral molecules with an extracellular mode of action. The development of 
neuraminidase inhibitors started in the middle 1970s, when the first structural 
analogues of sialic acid were described and denoted as DANA (2-deoxy-2,3-
didehydro- N-acetyl neuraminic acid) and its trifluoroacetyl derivative FANA 
(2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid).[40] At present, several 
licensed anti-influenza medications are available on the market, most notably 
the inhalant zanamivir with the trademark Releza®, and the orally administered 
oseltamivir (Tamiflu®) having excellent bioavailability and relatively long half-
life in vivo (Figure 1.4).[41, 42] 
 
 
Figure 1.4 Structure of neuraminidase inhibitors:  
zanamivir (1) and oseltamivir (2). 
 
In response to the emergence of some oseltamivir-resistant influenza strains, 
peramivir and laninamivir have been recently developed (Figure 1.5).[43, 44] 
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Figure 1.5 Structure of peramivir (1) and laninamivir (2). 
 
New-generation neuraminidase inhibitors are currently under investigation, 
e.g., multimeric forms of zanamivir,[45] dual-targeted bifunctional antivirals[46] 
and several herbal remedies, such as flavonols, alkaloids and saponins.[47]  
 
1.4 Influenza drug resistance 
 
The propagation of viruses in the presence of antiviral drugs increases the 
selection pressure for mutations in the viral target proteins, which results in the 
induction of virus drug resistance. As an example, adamantane resistant strains 
are typically characterised by a single substitution in the transmembrane region 
of the M2 ion channel.[48, 49] On the other hand, resistance to neuraminidase 
inhibitors can result from mutations in the neuraminidase active cavity, but also 
from amino acid substitutions on the molecular surface of the neuraminidase 
protein.[37, 50] It is noteworthy that resistance to adamantanes is acquired rapidly 
and by a high number of virus strains,[34] while neuraminidase inhibitor 
resistance has developed over a longer time period and occurs with a relatively 
lower frequency.[38] This may be due to the fact that some mutations 
significantly affect viral infectivity and ability to replicate in the host cell.  
Therefore, the capability of viruses to mutate the target proteins represents 
an obstacle for efficient treatment with these drugs. On the basis of the above it 
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is apparent the need to provide for new compounds against influenza virus able 
to overcome the disadvantages of the known therapies.[51, 52]  
Therefore, the identification of new target for therapy of influenza virus 
infection and development of new therapeutic agents are the global public health 
priority.  
 
1.5 Hemagglutinin: a new promising target  
 
An attractive antiviral strategy is the blocking of influenza virus entry into 
the host cell. This process is mediated by the viral hemagglutinin (HA), a 
glycosylated type I integral membrane protein. HA is responsible for the binding 
of the virus to the target cell and, after virus uptake into endosomes, fusion of 
the virus with the cell membranes.[53] 
The crystal structure of the HA molecule is a trimer with two structurally 
distinct regions: a stem, comprising a triple-stranded coiled-coil of alpha-
helices, and a globular head of antiparallel beta-sheet, positioned atop the 
stem.[54]  
The head contains the sialic acid receptor binding site, which is surrounded 
by the predicted variable antigenic determinants, designated A, B, C, and D in 
the H3 subtype[55] and Sa, Sb, Ca1, Ca2, and Cb in the H1 subtype (Figure 
1.6).[4] 
 
Chapter I: Hemagglutinin: a promising target against influenza virus 
- 16 - 
 
 
Figure 1.6 Ribbon diagram of an uncleaved hemagglutinin monomer from an influenza 
A virus (H1N1). The head contains the sialic acid receptor-binding site, which is 
surrounded by the five predicted antigenic sites (Sa, Sb, Ca1, Ca2, and Cb). The stem 
comprises helices A and B and the fusion peptide, as shown. Adapted from “The biology 
of influenza viruses,” by N. M. Bouvier and P. Palese, 2008, Vaccine, 26, 1-10. 
 
During virus replication, the HA protein is cleaved by serine proteases into 
HA1 and HA2; this post-translational modification is necessary for virus 
infectivity. The HA2 portion is thought to mediate the fusion of virus envelope 
with cell membranes, while the HA1 portion contains the receptor binding and 
antigenic sites.[56] Antibodies to HA neutralize virus infectivity, so virus strains 
evolve frequent amino acid changes at the antigenic sites; however, the stem-
head configuration of the HA molecule remains conserved among strains and 
subtypes. These relatively minor changes accumulate in a process called 
antigenic drift. Eventually, mutations in multiple antigenic sites result in a virus 
strain that is no longer effectively neutralized by host antibodies to the parental 
virus, and the host becomes susceptible again to productive infection by the 
drifted strain. 
Hemagglutinin has been chosen since it is the major surface protein of the 
Influenza A virus and is essential to the entry process so representing an 
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attractive target for antiviral therapy. An initial attachment of HA to specific 
receptors on the host cell surface and a membrane fusion of HA matured by 
protease digestion are required for virus infection. As a matter of fact, 
neutralizing compounds targeting HA represent a useful tool in neutralizing 
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Abstract 
Bovine lactoferrin (bLf) is a multifunctional glycoprotein that plays an 
important role in innate immunity against infections, including influenza.  
Therefore, bLf was considered a novel drug target for the inhibition of 
influenza virus infection. Previously, it was shown that inhibition of influenza 
virus hemagglutination and cell infection is entirely attributable to the C-lobe 
and that all major virus subtypes, including H1N1 and H3N2, are inhibited. By 
far-western blotting and sequencing studies, bLf was shown to bind to the HA2 
subunit, an HA region which is known to contain the universally conserved HA 
epitope. Moreover, molecular docking studies have identified some C-lobe 
fragments which inhibited virus hemagglutination and infection at picomolar 
concentration range. 
Besides contributing to explain the broad anti-influenza activity of bLf, these 
findings lay the foundations for exploiting bLf fragments as source of potential 
anti-influenza therapeutics. 
 
Keywords: Influenza, Bovine lactoferrin, C-lobe, Peptides, Antiviral. 
 
Abbreviations 
LF, lactoferrin; BLf, bovine lactoferrin; HI, hemagglutination inhibition 
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Lactoferrin (LF) is a non-haem iron-binding protein that is part of the 
transferrin protein family, whose function is to transport iron in blood 
serum.[1, 2] 
Lactoferrin was first isolated by Sorensen and Sorensen from bovine milk in 
1939. In 1960 it was concurrently determined to be the main iron binding 
protein in human milk by three independent laboratories.[3-5] 
LF  is commonly found in various secretory fluids, such as saliva, tears, nasal 
secretions, seminal and vaginal fluids, and in granules of polymorphonuclear 
leukocytes[6] of different mammalian species, including humans, cows, 
goats, horses, dogs, and several rodents.[7, 8]  
It is also found in considerable amounts in secondary neutrophil granules 
(15µg/106 neutrophils),[9] where it plays a significant physiological role. LF 
is an essential player of the natural immunity. LF possesses a greater iron-
binding affinity and is the only transferrin with the ability to retain this metal 
over a wide pH range,[10] including extremely acidic pH. It also exhibits a 
greater resistance to proteolysis. In addition to these differences, LF’s net 
positive charge and its distribution in various tissues make it a 
multifunctional protein. It is involved in several physiological functions, 
including: regulation of iron absorption in the bowel; immune response; 
antioxidant, anticarcinogenic and anti-inflammatory properties; protection 
against microbial infection, which is the most widely studied function to 
date; and inhibiting activity towards different pathogens.[7, 11-13] 
In particular, bLf has been recognized as potent inhibitor of different 
enveloped viruses, such as human cytomegalovirus,[14] herpes simplex 
viruses types 1 and 2,[15-18] human immunodeficiency virus,[19] human 
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hepatitis C virus,[20] hantavirus,[21] hepatitis B virus,[22] respiratory syncytial 
virus,[23] flavivirus,[24] alphavirus,[25] and phlebovirus.[26] 
 
2.2 Structure and properties 
 
Bovine lactoferrin (bLf) is a glycoprotein consisting of a single 
polypeptide chain of 689 amino acidic residues, with a molecular mass of 76 
kDa, which binds two iron atoms with very high affinity.[27] 
 BLf, like lactoferrin of other mammalian species, is folded in two 
symmetric and globular lobes: N-lobe (residues 1-333) and C-lobe (residues 
345-676) which are highly homologous with one another (33–41% 
homology). It is made up of α-helix and β-pleated sheet structures, which 
create two domains for each lobe (domains I and II). In bovine lactoferrin, 
the N1 stands for the sequences 1-90 and 251-333, N2 for 91-250, C1 for 
345-431 and 593-676, and C2 for 432-592.[28, 29] These two lobes are linked 
by a three-turn connecting helix, residues 334 and 344, which provide 
additional flexibility to the molecule (Figure 2.1).[28] Each lobe can bind a 
metal atom in synergy with the carbonate ion (CO3 
2−). The metals that it 
binds are the Fe2+ or Fe3+ ions, but it has also been observed bound to Cu2+, 
Zn2+ and Mn2+ ions.[7] 
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Figure 2.1 Schematic diagram of the bovine lactoferrin molecule. The N1 and N2 
domains are colored in yellow and pink, respectively, while the C1 and C2 domains 
are colored in green and blue, respectively. The interconnecting helix between the 
lobes is colored in orange. The two iron atoms are shown as red spheres. Adapted 
from “C-Lobe of Lactoferrin: The whole story of the half-molecule,” by S. 
Sharma, M. Sinha, S. Kaushik, P. Kaur and T. P. Singh, 2013, Biochemistry 
Research International, 2013, 1-8. 
 
Because of its ability to reversibly bind Fe3+, LF can exist free of Fe3+ 
(apo-LF) or associated with it (holo-LF),[30] and it has a different three-
dimensional conformation depending on whether it is binding Fe3+.[31] Apo-
LF has an open conformation, whilst holo-LF is a closed molecule with 
greater resistance to proteolysis (Figura 2.2).[8] 
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Figure 2.2 Structure of the iron-bound (holo) form (A) and iron-free (apo) form 
(B) of Lf. Adapted from “A structural framework for understanding the 
multifunctional character of lactoferrin,” by E. N. Baker and H. M. Baker, 2009, 
Biochimie, 91, 3–10. 
 
The iron-binding site is situated inside the interdomain cleft in each lobe. 
The iron-binding site consists of four residues: 2 tyrosines, 1 aspartate, and 
1 histidine. The iron-binding residues in N-lobe are Asp 60, Tyr 92, Tyr 192, 
and His 253 while the corresponding iron-binding residues in C-lobe are Asp 
395, Tyr 433, Tyr 526, and His 595. The iron-binding residues are 
coordinated to the ferric ion and a synergistic bidentate carbonate anion 
(Figura 2.3).[31] LF is a basic, positively charged protein with an isoelectric 
point of 8.0–8.5.[7] 
 
 
Chapter II: Bovine lactoferrin: a novel drug target for the inhibition of influenza virus 
infection 
 
- 32 - 
 
 
Figure 2.3 Schematic figure of the iron-binding site of lactoferrin. The iron atom 
is shown as a red sphere, while the interacting amino acid residues of lactoferrin 
are in yellow. The residue numbers correspond to N-lobe, while the corresponding 
residues of C-lobe are in brackets. Adapted from “C-Lobe of Lactoferrin: The 
whole story of the half-molecule,” by S. Sharma, M. Sinha, S. Kaushik, P. 
Kaur and T. P. Singh, 2013, Biochemistry Research International, 2013, 1-8. 
 
2.3 Biological functions of lactoferrin 
 
Several functions have been attributed to LF. It is considered a key 
component in the host’s first line of defence, as it has the ability to respond 
to a variety of physiological and environmental changes.[32] The structural 
characteristics of LF provide functionality in addition to the Fe3+ 
homeostasis function common to all transferrins: strong antimicrobial 
activity against a broad spectrum of bacteria, fungi, yeasts, viruses[33] and 
parasites;[34] anti-inflammatory and anticarcinogenic activities;[32] several 
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2.4 Scientific background 
 
Previously, Superti et al. have demonstrated that bLf binds to viral HA 
and inhibits hemagglutination and infection of all major virus subtypes, 
including H1N1 and H3N2.[37] 
In particular, by far-western blotting and sequencing studies, it 
demonstrated that lactoferrin binds to the HA2 subunit of viral HA, 
particularly to the fusion peptide, the only universally conserved epitope in 
all influenza virus hemagglutinin.[38] This behaviour explains the broad 
specificity of bLf and its C-lobe anti-influenza activity.[37] 
Moreover, molecular docking studies have shown that the bLf C-lobe 
binding to HA was mediated, in most cases, by three surface-exposed loops 
characterized by the following amino acid sequences: SKHSSLDCVLRP 
(aa 418–429, 1), AGDDQGLDKCVPNSKEK (aa 506–522, 2) and 
NGESSADWAKN, (3) (Figure 2.4). 
 
 
Figure 2.4 Putative binding mode of bLf C-lobe (white ribbon) with the HA stm 
(light grey solid surface): (A) close to the fusion peptide (dark grey surface); (B) in 
the cleft between two monomers. Selected bLf sequences correspond to the 
numbered black loops of bLf C-lobe: (1) SKHSSLDCVLRP; (2) 
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AGDDQGLDKCVPNSKEK; (3) NGESSADWAKN. Adapted from “Bovine 
lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza 
virus,” by M. G. Ammendolia, M. Agamennone, A. Pietrantoni, F. Lannutti, R. A. 
Siciliano, B. De Giulio, C. Amici, F. Superti, 2012, Pathog. Glob. Health., 106, 12-
19.  
 
Therefore, each peptide, tested by HI, has shown to be able to inhibit HA 
activity of all tested virus strains at concentrations much lower than those 
shown by the C-lobe (Table 2.1).  
 
Table 2.1 Interaction of SKHSSLDCVLRP, AGDDQGLDKCVPNSKEK, and 
NGESSADWAKN peptides with viral HA. Adapted from “Bovine lactoferrin-
derived peptides as novel broad-spectrum inhibitors of influenza virus,” by M. G. 
Ammendolia, M. Agamennone, A. Pietrantoni, F. Lannutti, R. A. Siciliano, B. De 
Giulio, C. Amici, F. Superti, 2012, Pathog. Glob. Health., 106, 12-19.  
 
 
Similarly to HI data, bLf-derived peptides were better inhibitors than the 
entire protein, their selectivity index being about one or two order of 
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Table 2.2 In vitro antiviral activity of SKHSSLDCVLRP, 
AGDDQGLDKCVPNSKEK, and NGESSADWAKN peptides towards influenza 
virus infection. Adapted from “Bovine lactoferrin-derived peptides as novel broad-
spectrum inhibitors of influenza virus,” by M. G. Ammendolia, M. Agamennone, A. 
Pietrantoni, F. Lannutti, R. A. Siciliano, B. De Giulio, C. Amici, F. Superti, 
2012, Pathog. Glob. Health., 106, 12-19.  
 
*CC50 the reciprocal substance dilution at which 50%of cells were protected from 
substance toxicity; °EC50 the reciprocal substance dilution at which 50% of cells 
were protected from the virus induced killing;ˆSI (selectivity index) the ratio 
between CC50 and EC50. 
The mean values of three independent experiments with standard errors are shown. 
 
This is the first demonstration that viral hemagglutination can be 
inhibited by a specific interaction with the HA2 subunit. As a matter of fact, 
neutralizing antibodies against influenza virus have been found to act by two 
different mechanisms, mirroring the dual functions of hemagglutinin: (i) 
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Abstract 
Bovine lactoferrin, more concretely its C-lobe, is able to prevent both 
influenza virus hemagglutination and cell infection.  
In this study, to deeper investigate the ability of lactoferrin derived peptides 
to inhibit influenza virus infection, we selected and synthesized new bovine 
lactoferrin C-lobe derived sequences that were assayed for their ability to 
prevent viral hemagglutination and cell infection.  
We identify three tetrapeptides endowed of broad anti-influenza activity and 
able to inhibit viral infection in a concentration range femto- to picomolar. Our 
data indicate that these peptides may constitute a non-toxic approach for 
potential applications as anti-influenza therapeutics. 
 
Keywords: Bovine lactoferrin; C-lobe; influenza virus; peptides; antivirals. 
 
Abbreviations 
Abbreviations used for amino acids and designation of peptides follow the 
rules of the IUPAC-IUB Commission of Biochemical Nomenclature in J. 
Biol. Chem. 1972, 247, 977-983. Amino acid symbols denote L-
configuration unless indicated otherwise. The following additional 
abbreviations are used: 
BLf, bovine lactoferrin; HA, hemagglutinin; HOBt, N-hydroxy-
benzotriazole; HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluoro-phosphate; HOAt, 1-Hydroxy-7-
azabenzotriazole; DIEA, N,N-diisopropylethyl-amine; DMF, N,N-
dimethylformamide; DCM, dichloromethane; NMP, N-Methyl-2-
pyrrolidone; TIS, triisopropylsilane; TFA, trifluoroacetic acid; GRK2, G 
Protein-Coupled Receptor Kinase 2; MDCK, Madin-Darby canine kidney; 
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Previously, Superti et al. have deeper investigated the mechanism of the 
anti-influenza virus effect of bLf and the role of its tryptic fragments (the N- 
and C-lobes) in the antiviral activity. In particular, they have evaluated the 
influence of bLf on hemagglutinin-mediated functions. Hemagglutinin has 
been chosen since it is the major surface protein of the Influenza A virus and 
is essential to the entry process so representing an attractive target for 
antiviral therapy. An initial attachment of HA to specific receptors on the 
host cell surface and a membrane fusion of HA matured by protease 
digestion are required for virus infection. As a matter of fact, neutralizing 
compounds targeting HA represent a useful tool in neutralizing viral 
infection.  
 
3.2 Aim of work  
 
By protein-protein docking calculations, it was demonstrated that the 
binding between bLf C-lobe and HA is mediated by specific C-lobe 
fragments (peptides 1, 2 and 3).[1] These peptides strongly inhibited viral 
hemagglutination and infection at low picomolar concentrations and were 
patented.[2] However, protein-protein docking calculations suggested the 
possible role of other loops of bLf C-lobe that can contribute to the binding 
to HA. Thus, to better analyze the molecular and structural requirements that 
determine the bLf C-lobe-HA interaction., firstly, we decided to perform a 
wider mapping of C-lobe domain by designing, synthesizing, and evaluating 
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a new library of bLf C-lobe derivatives, corresponding to the sequences 441-
454 (4), 478-500 (5), 552-563 (6), 619-630 (7), 633-638 (8), and 642-659 
(9) (Figure 3.1, in yellow). As observed in Figure 3.1, the peptides 1-9 (in 
purple and yellow) map almost the entire C-lobe domain.  
 
Figure 3.1 Cartoon representation of the bLf C-lobe. The patented sequences are 
depicted in purple and the newly synthesized sequences in yellow. 
 
3.3 Design, Results and Discussion 
 
3.3.1 Synthesis of C-lobe fragments (Peptides 4-9) 
 
The first part of the work focused the attention on different C-lobe bLf 
fragments (peptides 1, 4-9). These peptides were synthesized and tested in 
order to evaluate their effectiveness to inhibit the HA activity by influenza 
virus belonging to subtypes H1N1 and H3N2 (Table 3.1).  
 
3.3.1.1 Interaction with viral hemagglutinin 
The first step of influenza virus entry into susceptible cells depends on the 
interaction between the viral HA and a specific sialic acid-containing cell 
receptor. This interaction can be measured by agglutination of turkey 
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erythrocytes. Therefore, the binding between virus and bLf was tested by 
checking  the inhibition of viral hemagglutination activity. 
In this experiment, the following influenza A virus strains were used: 
A/RomaISS/02/08 H1N1 oseltamivir-sensitive virus, A/Parma/24/09 H1N1 
oseltamivir-resistant virus, and A/Parma/05/06 H3N2.  
 


















418-429 1 SKHSSLDCVLRP 0.0014 0.0014  0.0007  
506-522 2 AGDDQGLDKCVPNSKEK 0.0014 0.0014 0.0007 
553-563 3 NGESSADWAKN 0.7.10-6 0.3.10-6 0.0003 
441-454 4 KANEGLTWNSLKDK 12 3 12 
478-500 5 TGSCAFDEFFSQSCAPGADPKSR - - 97 





619-630 7 GKNGKNCPDKFC - - - 





 642-659 9 NDNTECLAKLGGRPTYEE - 2.500 - 
 
As shown in Table 3.1, three out of six peptides were able to prevent HA 
activity of all tested viruses. Notwithstanding these peptides exerted a strong 
antiviral action (nanomolar), their activity was lower than that previously 
described by peptides 1-3 (low picomolar).[1] For example, the compound 
most potent of this series, dodecapeptide 6, having a sequence similar to 
undecapeptide 3 proves to be 3-4 orders of magnitude less potent than 
reference peptides.[1] 
According to these results, peptide 1 inhibits influenza virus 
hemagglutination at picomolar concentration, proving to be a potent 
antiviral peptide. During my PhD, I considered peptide 1 as a valuable 
starting point for the development of a novel class of antiviral drugs effective 
against influenza virus. 
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3.3.2 Design of peptides 10-17 
 
In order to optimize the inhibitory activity of the 418SKHSSLDCVLRP429 
fragment (1) and to identify more potent and selective compounds, two different 
approaches were used: i) addition of four amino acid residues at both the N- and 
C-terminals (compounds 10-12); ii) a truncation study, carried out via a 
systemic reduction of four residues at both the N- and C-terminals of the peptide 
1, to identify the shortest amino acid sequence needed for the peptide activity 
(compounds 13-17) (Table 3.2).  
 
3.3.2.1 Interaction with viral hemagglutinin 
As shown in Table 3.2, N-terminal truncation strategy led to the most 
interesting results. Thus, octapeptide 13 was the most effective fragment of this 
series to prevent HA activity of all tested viruses in a concentration range 0.15 
to 0.7 pM. 
C-terminal tetrapeptide of 1, peptide 14, lost activity on all strains used in the 
assay, indicating the importance of N-terminal residue of 1 for the 
hemagglutination inhibition activity, while the tetrapeptide 15 maintained the 
same inhibition level of 1 on Influenza A/Roma-ISS/02/08 H1N1 strain. Peptide 
15 showed a remarkable inhibitory selectivity against this strain (1000 fold) 
compared to the Parma strains. This selectivity was also observed with the 
compounds 16 and 17, derived from the C-terminal deletion on the lead 
sequence 418-429, which were 15-40 fold more potent against A/Roma strain 
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418-429 1 SKHSSLDCVLRP 0.0014 0.0014 0.0007 
414-433 10 NRKSSKHSSLDCVLRPTEGY 0.3 6 0.0014 
414-429 11 NRKSSKHSSLDCVLRP - 12 0.4 
418-433 12 SKHSSLDCVLRPTEGY 0.7 0.1 0.03 
422-429 13 SLDCVLRP 0.0007 0.00015 0.0004 
426-429 14 VLRP 0.7 0.15 1.5 
422-425 15 SLDC 0.0014 6 1.5 
418-425 16 SKHSSLDC 0.3 12 12 
418-421 17 SKHS 0.1 1.5 12 
The peptides 13-17 are acetylated and amidated at N-terminal and C-terminal, respectively. 
 
3.3.2.2 Neutralization of influenza virus  
Next, it has been examined whether, and to what extent, peptides most 
potent of first series (4, 6, 8) and fragments 13-17 derived from 1 could affect 
virus replication in Madin-Darby canine kidney cells (MDCK) by 
neutralization assay. 
The influenza A virus strains A/RomaISS/02/08 H1N1 oseltamivir-sensitive 
virus, A/Parma/24/09 H1N1 oseltamivir-resistant virus, and A/Parma/05/06 
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1 SKHSSLDCVLRP 4±0.37 >6.25.106 3.1±0.12 >8.106 5.8±0.7 >4.4.106 
4 KANEGLTWNSLKDK 1±0.15 >2.5.107 50.000±250 >5.102 1.000±360 >2.5.104 
6 TNGESTADWAKN 400±0.02 >6.25.104 50.000±230 >5.102 10.000±120 >2.5.103 
8 KSETKN 0.5±0.01 >5.107 500±0.46 >5.104 400.000±210 >0.65.102 
13 SLDCVLRP 0.3±0.5 >8.33.107 2.5±0.37 >1.107 300±0.2 >8.33.104 
14 VLRP 0.45±0.1 >5.55.107 1±0.05 >2.5.107 250±0.42 >1.105 
15 SLDC 0.5±0.001 >5.107 4.6±0.05 >5.4.106 4.3±0.03 >5.8.107 
16 SKHSSLDC 80±0.19 >3.125.105 0.1±0.001 >2.5.108 5.0±0.45 >5.106 
17 SKHS 3±0.61 >8.33.106 0.048±0.0012 >5.2.108 5.0±0.02 >5.106 
a EC50: the reciprocal substance dilution at which 50% of cells were protected from the virus induced 
killing; ^SI (selectivity index): the ratio between CC50 (the reciprocal substance dilution at which 50% 
of cells were protected from substance toxicity, corresponding to > 25 μM) and EC50; The mean values 
of 3 independent experiments with standard errors are shown.  
 
According to the results showed in Table 3.3, peptides 4, 6, and 8 were able 
to prevent infection of all tested viruses in a concentration range from about 
0.5 pM to 400 nM. At these concentrations, the peptides of the first series 
are the most toxic (SI ≈ 10-2/10-4). The octapeptide 13 (SLDCVLRP), the 
most active in the prevention of viral hemagglutination (HI titer 0.15-0.7 
pM, Table 3.2), conserved a good antiviral activity against the two A/Roma 
and A/Parma H1N1 strains, with EC50 values of 0.3 and 2.5 pM, 
respectively, but lost activity against H3N2 strain respect to 1 (≈50 fold, 
EC50 = 300 pM). 
Tetrapeptide 14, containing a net positive charge (Arg428), showed a similar 
activity profile to peptide 13, in particular, 14 was more active against both 
H1N1 strains compared to reference peptide 1. Tetrapeptide 15, with net 
charge opposite to 14 (Asp424), was strongly effective against 
A/Parma/05/06 H3N2 strain at 4.3 pM. Derivatives obtained by C-terminal 
truncation of 1, peptides 16 and 17, presented a different behaviour. 
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Octapeptide 16 was 30 and 10 fold more potent than 1 and 13, respectively, 
to prevent viral infection against A/Parma/24/09 H1N1 strain, while it was 
20 and 270 fold less active than these, against A/Roma- ISS/2/08 H1N1 
strain. Tetrapeptide 17, containing two positive residues (Lys419-Hys420) 
retrieves antiviral activity on this last strain, maintaining high antiviral 
activity at femto- and pico-molar concentration against both A/Parma H1N1 
and H3N2 strains, respectively. These results suggest that tetrapeptides 14, 
15, and, in particular 17 could be good starting point in the search for new 
peptidomimetics and small molecules candidates for influenza virus 
treatment as well as in the search of new peptide formulation with the same 
aim. 
 
3.3.3 Peptide 14 modifications (Peptides 18-23) 
 
Focused on peptide 14, we evaluated the importance of the net positive 
charge (Arg428) on the biological activity.  Arg at position 3 was replaced 
with positive charged amino acid, lysine (Lys) and ornithine (Orn), and 
aminoacid with net charge opposite, glutamic acid (Glu) and aspartic acid 
(Asp).  
We also synthesized peptides 22-23, obtained from N- and C- terminal 
deletions of peptide 14 (Table 3.4). 
 
3.3.3.1 Interaction with viral hemagglutinin 
As shown in Table 3.4, no compound generated through the substitution 
of Arg at position 3 with positive and negative charged amino acid and N- 
and C- terminal deletions, was able to inhibit HA in a greater extent of 
peptide 14. 
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The substitution of Arg with positive charged amino acid, Lys and Orn, 
determines an increase of the antiviral potency on influenza A/Roma-
ISS/2/08 A/H1N1 virus subtype and a dramatic loss or decrease of activity 
against the other two influenza Parma virus subtypes, respectively. 
In derivatives 20 and 21, the absence of positive charge by substitution of 
Arg3 with aminoacid with net charge opposite, Glu and Asp, induces a 
dramatic loss of activity against influenza H1N1 virus subtypes, increasing 
the antiviral potency on Parma H3N2 strain.  
Peptides 22 and 23, obtained by N- and C- terminal deletions, appear not 
inhibit notably HA activity compared to peptides 14. 
 

















14 VLRP 0.7 0.15 1.5 
18 VLKP 0.0031 - 8.6 
19 VLOP 0.0014 - 12 
20 VLEP - 6 0.1 
21 VLDP - 7.1 
 
0.6 
 22 VLR - 3 3000 





All peptides are acetylated and amidated at N-terminal and C-terminal, respectively. 
 
3.3.4 Alanine scanning approach (Peptides 24-31) 
 
Through a truncation library, we identified the tetrapeptides 15 and 17, 
which were able to bind HA and inhibit cell infection. In order to generate 
peptides with improved biological activity, we decided to apply to peptides 
15 and 17 an Alanine scanning approach, a classical chemical tecnique to 
check the relevance of side chains of each aminoacidic residue in the 
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interaction with the target molecule (peptides 24-31, Table 3.5). This 
approach resulted in the generation of a panel of eight peptides, named 
peptide 24 to 31. All new derivatives were tested for the assessment of their 
ability to inhibit viral hemagglutination and cell infection. 
 
3.3.4.1 Interaction with viral hemagglutinin 
As shown in Table 3.5, the substitution of Ser1 and Leu2 with an alanine 
determines a significant increase of inhibitory potency of the corresponding 
analogues 24 and 25 compared to reference peptide 15. In derivative 26, the 
absence of negative charge by substitution of Asp3 with Ala induces a decrease 
of activity against all influenza strains. 
Peptide 30 loses the inhibitor potency on all influenza strains. It showed that 
Asp3 and Cys4 are important amino acids for inhibitory activity of all influenza 
virus subtypes. 
The data showed that Ser1, Lys2, and His3 of peptide 17 are key amino acids 
for the antiviral activity against all influenza strains used in the assay. The 
substitution of a hydroxyl chain (Ser 4) with a residue more lipophilic (Ala) 
determines a significant increase of inhibitory potency of the corresponding 
analogue 31 compared to reference peptide 17. In derivative 29, the absence of 
positive charge by substitution of Lys2 with Ala induces a dramatic loss of 
activity against influenza A/Roma-ISS/2/08 A/H1N1 virus subtype, increasing 
the antiviral potency on the other two influenza Parma virus subtypes. Peptide 
30 increases the inhibitor potency on Parma H1N1 strain, showing that His3 is 
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15 SLDC 0.0014 6 1.5 










 26 SLAC 1.7 8.3 
 
4 
 27 SLDA - - 3.7 
17 SKHS 0.1 1.5 12 
28 AKHS 0.6 
 
- 12 
29 SAHS - 0.005 0.023 
30 SKAS 0.1 
 
0.0015 - 
31 SKHA 0.047 0.0014 0.0003 
All peptides are acetylated and amidated at N-terminal and C-terminal, respectively. 
 
3.3.4.2 Neutralization of influenza virus  
We have examined the ability of peptides 24, 25 and 31derived from 15 and 
17 to affect virus replication in Madin-Darby canine kidney cells (MDCK) by 
neutralization assay. 
However, it has been demonstrated that no compound, generated through the 
Ala scan analysis, was able to inhibit virus replication in a greater extent of 
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15 SLDC 0.5±0.001 >5.107 4.6±0.05 >5.4.106 4.3±0.03 >5.8.107 














17 SKHS 3±0.61 >8.33.106 0.048±0.0012 >5.2.108 5.0±0.02 >5.106 







a EC50: the reciprocal substance dilution at which 50% of cells were protected from the virus induced 
killing; ^SI (selectivity index): the ratio between CC50 (the reciprocal substance dilution at which 50% 
of cells were protected from substance toxicity, corresponding to > 25 μM) and EC50; The mean values 





The direct application of proteins and peptides as medicinal entities has 
some severe limitations, including high degradation by proteolytic enzymes 
and poor cell membrane permeability. Many of these problems could be 
avoided by an alternative, modular system with a basis set of "unnatural" 
monomers. Once an interesting compound has been identified from a library 
of such nonpeptide polymers, it can serve as a lead for drug discovery, 
further along the road to a metabolically stable drug. Optimized analogs of 
a lead compound could then be developed rapidly due to the modular 
synthetic nature of these compounds. 
 
3.3.6 Design of N-methyl peptides (Peptides 32-41) 
 
N-Methylation of the peptide backbone has been shown to be a valuable tool 
in structure-activity relationship studies.[3.5] 
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The replacement of natural amino acids for N-methyl amino acids in 
biologically active peptides has resulted in analogs with improved 
pharmacological properties, such as enzymatic stability,[6, 7] receptor 
selectivity,[8, 10] enhanced potency[11-13] and bioavailability.[14-17] The N-
methylation of backbone confers high affinity toward the targets, proteolytic 
stability, membrane permeability, and conformational rigidity to the peptides. 
Thus, in peptide chemistry N-methylation is considered as one of the most 
attractive and suitable modifications of a peptide structure.[18, 19] 
Hence, focused on tetrapeptides 15 and 17 we decided to synthesize the 
corresponding N-methyl peptides (peptides 32-41, Table 3.7). Every amide 
bond and, subsequently, the whole peptide backbone (compound 41, Figure 3.2) 
were replaced sequentially by the corresponding N-methylated unit.  
 
 
Figure 3.2 Structure of compound 41. 
 
With the synthesis of a series of ten N-methylated peptides we investigated if 
N-methylation of a single peptide bond and all peptide bonds in the lead 
structures 15 and 17 has similar positive effects on activity.  
 
3.3.6.1 Interaction with viral hemagglutinin 
The influence of this N-methylation scan on biological activity was 
investigated and revealed a significant increase of inhibitory potency of the 
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corresponding analogues 35 and 40 compared to reference peptides. The other 
peptides showed lower activities. 
 

















15 SLDC 0.0014 6 1.5 
32 (N-Me)SLDC - 8.7 2.3 
33 S(N-Me)LDC 1.56 7.13 0.87 
34 SL(N-Me)DC 2.33 - - 
35 SLD(N-Me)C 0.0041 3.32 0.41 
36 (N-Me)[SLDC] 3.7 7.91 - 
17 SKHS 0.1 1.5 12 
37 (N-Me)SKHS 0.3 5.7 13.6 
38 S(N-Me)KHS 0.2 3.23 2.6 
39 SK(N-Me)HS 0.13 6.07 - 
40 SKH(N-Me)S 0.07 1.03 6.7 
41 (N-Me)[SKHS] 0.67 - 11.17 
All peptides are acetylated and amidated at N-terminal and C-terminal, respectively. 
 
3.3.6.2 Neutralization of influenza virus  
Next, we have examined the ability of peptides 35 and 40 to affect virus 







Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 
- 57 - 
 


















15 SLDC 0.5±0.001 >5.107 4.6±0.05 >5.4.106 4.3±0.03 >5.8.107 







17 SKHS 3±0.61 >8.33.106 0.048±0.0012 >5.2.108 5.0±0.02 >5.106 







a EC50: the reciprocal substance dilution at which 50% of cells were protected from the virus induced 
killing; ^SI (selectivity index): the ratio between CC50 (the reciprocal substance dilution at which 50% 
of cells were protected from substance toxicity, corresponding to > 25 μM) and EC50; The mean values 
of 3 independent experiments with standard errors are shown.  
 
However, these peptides have not shown increased antiviral activity 
compared to peptides 15 and 17. 
 
3.3.7 Design of peptoids (Compounds 42-51)  
 
Peptoids are peptidomimetic molecules that comprise of repeating poly-N-
substituted glycine units (NGS).[20] They are a readily accessible class of 
synthetic, non-natural peptide mimic of modular design into which a plethora 
of structural elements can be readily incorporated. In terms of structure, 
peptoids differ from peptides in that their side-chain functionality is bonded to 
the nitrogen of the poly-amide backbone, rather than the α-carbon, leading to an 
achiral, flexible oligomeric backbone devoid of hydrogen bond donors (Figure 
3.3). This repeating N-alkyl amide backbone motif affords peptoids with an 
increased stability towards proteolytic degradation compared to analogous 
peptides.[21] Compared to α-peptides, NSG’s have distinct secondary structures 
(e.g., helices) characterized by steric and electronic interactions that are stable 
over a wider range of solvent, ionic and thermal conditions.[22] Further, the NSG 
backbone is not a substrate for commonly encountered proteases, which leads 
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to backbone proteolytic stability. In addition, NSG’s can be more hydrophobic 
and they possess superior cellular permeability.[21-28] The schematic comparison 
of peptides and peptoids, provided in Figure 3.3, shows the similarities in the 
spacing of the side chains and the carbonyl groups, and the differences in the 
chirality of the two monomers.  
 
 
Figure 3.3 The comparision of (a) peptide and (b) peptoid 
 
Hence, focused on tetrapeptides 15 and 17 we decided to synthesize the peptoid 
analogues (compound 51, Figure 3.4). 
 
 
Figure 3.4 Structure of compound 51. 
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3.3.7.1 Interaction with viral hemagglutinin 
Peptoids (42-51) were tested to verify if they inhibit hemagglutinin activity. 
Here, it has been demonstrated that no compound was able to inhibit HA activity 
in a greater extent of peptides 15 and 17 (compounds 42-51, Table 3.9).  
 

















15 SLDC 0.0014 6 1.5 
42 NhSerLeuAspCys 1.3 3.7 1.47 
43 SerNLeuAspCys 4.6 3.4 9.87 
44 SerLeuNAspCys 1.3 5.7 1.95 
45 SerLeuAspNhCys 0.87 4.5 - 
46 NhSerNLeuNAspNhCys 0.0023 2.17 0.36 
17 SKHS 0.1 1.5 12 
47 NhSerLysHisSer 1.47 3.3 - 
48 SerNLysHisSer 2.16 - 3.7 
49 SerLysNHisSer 4.1 0.19 - 
50 SerLysHisNhSer 0.67 3.66 5.7 
51 NhSerNLysNHisNhSer 0.067 0.13 1.23 
All peptides are acetylated and amidated at N-terminal and C-terminal, respectively. 
 
3.3.7.2 Neutralization of influenza virus  
Next, we have examined the ability of peptoids 46 and 51 to affect virus 
replication in Madin-Darby canine kidney cells (MDCK) by neutralization 
assay.  
As shown in Table 3.10, virus replication was inhibited by peptides 46 and 
51 at concentrations several logs lower than peptides 15 and 17.  
 
 
Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 
- 60 - 
 


















15 SLDC 0.5±0.001 >5.107 4.6±0.05 >5.4.106 4.3±0.03 >5.8.107 







17 SKHS 3±0.61 >8.33.106 0.048±0.0012 >5.2.108 5.0±0.02 >5.106 







a EC50: the reciprocal substance dilution at which 50% of cells were protected from the virus induced 
killing; ^SI (selectivity index): the ratio between CC50 (the reciprocal substance dilution at which 50% 
of cells were protected from substance toxicity, corresponding to > 25 μM) and EC50; The mean values 
of 3 independent experiments with standard errors are shown.  
 
3.4 NMR analysis of peptide 1 and 17.  
 
The solution-state structure (HFA/H2O) of the oligopeptide SKHSSLDCVLRP 
(1) was obtained by 2D NMR spectroscopy. In details, according to standard 
procedures,[29] the chemical shift assignments of the 1H resonances (Table S1) 
have been achieved by using DQF-COSY,[30] TOCSY[31] and NOESY[32] 
experiments. A set of 117 inter-proton distance restraints were collected from 
2D-NOESY NMR experiments (tmix = 400 ms) and used in simulated annealing 
protocol of the software CYANA 2.1.[33] The NMR structure bundle (Figure 3.5, 
left) of SKHSSLDCVLRP shows high structural agreement with RMSD of 0.29 
Å referenced to the backbone atoms. By means of PROMOTIF software,[34] the 
quantitative analysis of φ and ψ dihedral angles of the representative structures 
of SKHSSLDCVLRP was carried out, highlighting a global turn conformation. 
In particular, 1 contains four β-turns (type IV) formed by residues: 2-5, 4-7, 6-
9 and 7-10, (Table S3). It was also observed a γ-turn structure involving the 
residues Val9-Arg11 (Table S3).  
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Figure 3.5 On the left, superposition of backbone atoms of twenty NMR structures of 1 
(orange ribbons) generated by using CYANA 2.1. On the right, the average NMR 
derived structures of 1. The atoms are depicted in tube and colored by atom types (O, 
red; N, blue; S, yellow; polar hydrogen, white). The backbone C atoms of 1 are colored 
as for the ribbons and the side chain C atoms are in grey. The dashed lines indicate 
intramolecular H-bonds responsible of the global fold. 
 
The overall turn conformation observed for 1 is in line with spatial arrangement 
of the loop Ser418-Pro429 of C-terminal lobe of lactoferrin (PDB ID: 3IB0). In 
particular, we observed that the helix 310 formed by Cys425-Leu427 of protein 
loop is overlapped with the γ-turn of 1 centered on Val9-Arg11 (Figure 3.6a). 
Moreover, we observed a very good superimposition between 1 and the loop 
Ser418-Pro429 in the first four amino acids (SKHS, Figure 3.6b), suggesting 
this conformation as a structural requirement for the resulting peptide activity 
as shown by 17.  
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Figure 3.6 a) Superimposition of loop Ser418-Pro429 (yellow and blue ribbon) of 
lactoferrin (PDB ID: 3IB0) and 1 (orange and black ribbon). The blue and black 
portions indicate the helix 310 of Ser418-Pro429 and the γ-turn of 1, respectively. b) 
Superimposition of first four amino acids (SKHS) of 1 (cyan) and loop Ser418-Pro429 
(tan). The atoms are depicted in tube and colored by atom types (O, red; N, blue). The 
C atoms of 1 and loop Ser418-Pro429 are colored as for tube. 
 
Similarly to 1, we tried to assign the 1H resonances of tetrapeptide 17 (SKHS) 
in HFA/H2O, but most of resonances resulted overlapped. Thus, we assigned 
the 1H resonances in DMSO (Table S2).[35, 36] of tetrapeptide 17 (SKHS)  We 
also attempted to determine the solution structure of 17 by collecting interproton 
distance restraints from 2D-NOESY and 2D-ROESY[37] experiments at 
different mixing time, but the very low number of inter-residue NOE effects 
hampered this task. This was due to the expected high flexibility of the 
tetrapeptide in solution, nevertheless we can assume that the preferred 
conformation of 17 is similar to the spatial arrangement observed for 1 and the 
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3.5.1 General procedure for synthesis  
 
The synthesis of peptides (1, 8, 13-31) was performed according to the solid 
phase approach using standard Fmoc methodology in a manual reaction 
vessel.[38] The first amino acid was linked onto the Rink resin previously 
deprotected by a 25% piperidine solution in N, N-dimethylformamide (DMF) 
(1 × 5min and 1 × 25min). 
The following protected amino acids were then added stepwise. Each coupling 
reaction was accomplished using HBTU and HOBt as coupling reagents in the 
presence of DIPEA. The Nα-Fmoc protecting groups was removed by treating 
the protected peptide resin with a 25% solution of piperidine in DMF.  
In addition, after each step of deprotection and after each coupling step, Kaiser 
test was performed to confirm the complete removal of the Fmoc protecting 
group, respectively, and to verify that complete coupling has occurred on all the 
free amines on the resin.  
The N-terminal Fmoc group was removed as described above and the peptides 
were acetylated adding a solution of Ac2O/DCM (1:3) shaking for 30 min. 
Finally, the peptides were released from the resin with trifluoroacetic acid 
(TFA)/ triisopropylsilane (iPr3SiH) / H2O (90:5:5) for 3 h. The resin was 
removed by filtration, and the crude peptide was recovered by precipitation with 
cold anhydrous ethyl ether to give a white powder and then lyophilized (Scheme 
3.1). 
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Scheme 3.1 Synthesis of peptide 17. 
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3.5.2 Microwave peptide synthesis 
 
Microwave- assisted SPPS is a useful and reliable tool for the synthesis of 
long peptides and "difficult" sequence. Fast and precise heating by microwave 
irradiation during solid-phase peptide synthesis (SPPS) can reduce reaction 
times as well as provide better purities and greater yields for the synthesis of 
difficult peptides.[39] Therefore, we synthesized peptides 4-7, 9, 10-12 using an 
Automated Microwave Peptide Synthesizer from Biotage AB (Initiator + 
Alstra™) (Figure 3.7).  
 
 
Figure 3.7 The Biotage Initiator + Alstra™. 
 
Peptides were synthesized on a Wang-ChemMatrix. The first amino acid was 
linked on to the resin in the presence of DMAP, using as coupling reagent 
HBTU, HOAt and DIEA in N-methyl-2-pyrrolidone (NMP).[40] The Nα-Fmoc 
protecting groups were removed by treating the protected peptide resin with a 
25% solution of piperidine in DMF (1 × 3 min, 1 × 10 min) at room temperature. 
The following protected amino acids were then added on to the resin stepwise. 
Coupling reactions were performed using Nα-Fmoc amino acids, using as 
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coupling reagent HBTU, HOAt and DIEA in NMP. All couplings were achieved 
for 10 min at 75 ºC (2x) and 2x45 min at RT for histidine and cysteine couplings 
to avoid the epimerization. After each coupling step, the Fmoc protecting group 
was removed as described above. The resin was washed with DMF (4 × 4.5 ml) 
after each coupling and deprotection step. Finally, peptides were released as 
described above. 
 
3.5.3 Synthesis of N-methyl peptides  
 
In SPPS the coupling of N-methyl amino acids generally occurs in low yield 
and in many cases requires expensive coupling reagents and double coupling. 
Therefore, we decided to synthesize N-methyl peptides (32-41) using 
microwave (MW) irradiation.[41, 42] MW irradiation was provided by an 
Automated Microwave Peptide Synthesizer from Biotage AB (Initiator + 
Alstra™) (Figure 3.7). Fmoc-Rink amide resin was used as solid phase support 
(Scheme 3.2). Initially, the resin was deprotected with 20% piperidine/DMF. 
The protected amino acids were then coupled using HBTU and HOBt as 
coupling reagents in the presence of DIPEA and the mixture was irradiated for 
20 min with a maximum temperature of 35 °C. In addition, after each step of 
deprotection and after each coupling step, chloroanyl test was performed. [43] To 
ensure complete Nα-Fmoc protecting groups removal, we followed standard 
treatments with 20% piperidine in DMF solutions and two extra treatments of 5 
min with piperidine : DBU: toluene : DMF (5: 5 : 20 : 70, v/v) 
The N-terminal Fmoc group was removed and the peptides were acetylated as 
described above. Final peptides were cleaved from the resin with the following 
cleavage cocktails: TFA/DCM (95:5 v/v) for 90 min. Peptides were precipitated 
by addition of cold diethyl ether, the solution was decanted, and the solid was 
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triturated with cold diethyl ether, which was decanted again. This process was 
repeated twice (Scheme 3.2). 
 
 
Scheme 3.2 Synthesis of peptide 41. 
 
3.5.4 Synthesis of peptoids  
 
In the solid-phase synthesis of peptoid, two different approaches can be used 
to introduce an N-alkylglycine (peptoid residue) on the growing peptide chain: 
(i) the N-substituted glycine derivative, suitably protected at the tertiary 
nitrogen atom, can be separately prepared and directly utilized as building block 
in the solid phase procedure (monomer method),[44, 45] or (ii) the peptoid residue 
is built during the peptide chain elongation by a combination of two 
submonomers, an haloacetic acid and a primary amine (submonomer 
method).[20]  
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To speed up the synthesis of peptoid, we optimized a procedure based on the 
submonomer method, which makes possible a direct assembling of the 
functionalized peptoid residue starting from commercially available reagents.  
For the synthesis of compounds 42-51, the peptoid residue is built during the 
peptide chain elongation by a combination of two submonomers, an haloacetic 
acid and a primary amine (submonomer method).  
Initially the Rink resin was deprotected by a 25% piperidine solution in N, N-
dimethylformamide (DMF) for 30 min.  
Bromoacetic acid was then coupled to the NH2-peptide resin in the presence of 
N, N’-diisopropylcarbodiimide (DIC), and the halogen was displaced with a 
large excess of primary amine. Further elongation of the peptide chain was 
carried out according to the standard protocol, with the addition of Bromo acetic 
acid and the appropriate amine. The last N-alkylglycine residue was acetylated 
as described above. Simultaneous deprotection and cleavage of peptoids from 
the resin carried out. 
Typical cycle times for NSG oligomer synthesis are of the order of 150-180 
minutes for the completion of one monomeric residue addition at room 
temperature. Thus, we synthetized peptoids using continuous-flow (CF) 
technique. Through the application of a CF technique these compounds were 
synthetized in high yields and with low amino acid and solvent consumption. 
This approches offer an great number of advantages over conventional batch 
procedures, for example, the efficient mixing of substrates, faster heat and mass 
transfer, and shorter reaction times (Figure 3.8).[46-54]  
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Figure 3.8 Vapourtec Flow Chemistry 
 
The synthesis is illustrated in Scheme 3.3: 
 
 
Scheme 3.3 Synthesis of compound 51. 
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The crude compounds were purified by preparative RP-HPLC. Analytical 
HPLC indicated a purity  greater than 98%, and molecular weights were 




The present study describes the identification of three C-lobe bLf-derived 
tetrapeptides as the minimum fragments expressing the broad anti-influenza 
activity of bLf. Peptides 14 (VLRP), 15 (SLDC), and 17 (SKHS) were designed 
from the fragment 418-429 (1, SKHSSLDCVLRP), which is involved in the C-
lobe bLf-HA interaction. These tetrapeptides retain the inhibitory potency of 
the fragment 418-429 and inhibit the influenza virus hemagglutination and cell 
infection in a concentration range of femto- to picomolar. NMR spectroscopy 
analysis performed on compounds 1 showed a global turn conformation for this 
peptide and hypothesized the preferred bioactive conformation of our 
tetrapeptides. Our results strongly encourage the pursuit of this path for the 
development of a novel class of anti-influenza drugs. 
 
3.7 Experimental section 
 
Nα-Fmoc-protected amino acids, Wang resin, Rink amide-resin, 1-Hydroxy-7-
azabenzotriazole (HOAt), N-hydroxy-benzotriazole (HOBt), 2-(1H-
benzotriazole-1-yl)- 1, 1, 3, 3-tetramethyluronium hexafluoro-phosphate 
(HBTU), N, N-diisopropylethyl-amine (DIPEA), Piperidine and Trifluoroacetic 
acid were purchased from Iris Biotech (Germany). Wang-ChemMatrix and 
Rink-ChemMatrix resins were purchased from Biotage AB (Sweden). Peptide 
synthesis solvents, reagents, as well as CH3CN for high performance liquid 
chromatography (HPLC) were reagent grade and were acquired from 
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commercial sources and used without further purification unless otherwise 
noted. 
 
3.7.1 Synthesis of linear derivatives (peptides 1, 8, 13-31)  
 
The synthesis of bLf analogues (1, 8, 13-31) was performed according to the 
solid phase approach using standard Fmoc methodology in a manual reaction 
vessel.[55, 56] 
 The first amino acid, Nα-Fmoc-Xaa-OH (Xaa = Pro, Asn(Trt), Cys(Trt), 
Ser(tBu), Arg(Pbf), Ala), was linked on to the Rink resin (100–200 mesh, 1% 
DVB, 0.59 mmol/g) previously deprotected by a 25% piperidine solution in N, 
N-dimethylformamide (DMF) for 30 min.  
The following protected amino acids were then added stepwise: Nα-Fmoc-
Arg(Pbf)-OH, Nα-Fmoc-Leu-OH, Nα-Fmoc-Val-OH, Nα-Fmoc-Cys(Trt)-OH, 
Nα-Fmoc-Asp(OtBu)-OH, Nα-Fmoc-Ser(tBu)-OH, Nα-Fmoc- 
His(N(im)trityl(Trt))-OH, Nα-Fmoc-Lys(Boc)-OH, Nα-Fmoc-Thr(tBu)-OH, 
Nα-Fmoc-Glu(OtBu)-OH, Fmoc-Orn(Boc)-OH, Nα-Fmoc-Ala-OH. Each 
coupling reaction was accomplished using a 3-fold excess of amino acid with 
HBTU and HOBt in the presence of DIPEA (6 eq.). The Nα-Fmoc protecting 
groups were removed by treating the protected peptide resin with a 25% solution 
of piperidine in DMF (1 × 5 min and 1 × 25 min). The peptide resin was washed 
three times with DMF, and the next coupling step was initiated in a stepwise 
manner. The peptide resin was washed with DCM (3×), DMF (3×), and DCM 
(3×), and the deprotection protocol was repeated after each coupling step. In 
addition, after each step of deprotection and after each coupling step, Kaiser test 
was performed to confirm the complete removal of the Fmoc protecting group, 
respectively, and to verify that complete coupling has occurred on all the free 
amines on the resin. The N-terminal Fmoc group was removed as described 
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above, and the peptides were acetylated adding a solution of Ac2O/DCM (1:3) 
shaking for 30 min. Finally, the peptides were released from the resin with 
TFA/TIS/H2O (90:5:5) for 3 h. The resin was removed by filtration, and the 
crude peptide was recovered by precipitation with cold anhydrous ethyl ether to 
give a white powder and then lyophilized. 
 
3.7.2 Microwave peptide synthesis 
 
Peptides 4-7, 9-12 were synthesized using an Automated Microwave Peptide 
Synthesizer from Biotage AB (Initiator + Alstra™). Peptides were synthesized 
on a Wang-ChemMatrix resin (0.150 g, loading 0.3 mmol/g). The first amino 
acid was linked on to the resin in the presence of DMAP (2.4 eq.), using as 
coupling reagent HBTU (4eq, 0.6M), HOAt (4eq, 0.5M) and DIEA (8eq, 2M) 
in N-methyl-2-pyrrolidone (NMP).[57] The resin was then washed with DMF (4 
× 4.5ml). The Nα-Fmoc protecting groups were removed by treating the 
protected peptide resin with a 25% solution of piperidine in DMF (1 × 3 min, 1 
× 10 min) at room temperature. The following protected amino acids were then 
added on to the resin stepwise. 
Coupling reactions were performed using Nα-Fmoc amino acids (4.0 eq., 0.5 
M), using as coupling reagent HBTU (4eq, 0.6M), HOAt (4eq, 0.5M) and DIEA 
(8eq, 2M) in N-methyl-2-pyrrolidone (NMP). All couplings were achieved for 
10 min at 75 ºC (2x) and 2x45 min at RT for histidine and cysteine couplings to 
avoid the epimerization. After each coupling step, the Fmoc protecting group 
was removed as described above. The resin was washed with DMF (4 × 4.5 ml) 
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3.7.3 Synthesis of N-methyl peptides (compound 32-41) 
 
Fmoc-Rink amide resin (100–200 mesh, 1% DVB, 0.75 mmol/g) was placed 
in a peptide synthesis vessel, swollen in DMF, and deprotected with 5 ml of 
20% piperidine/DMF for 4 min. Washings between the first deprotection, 
coupling, and subsequent deprotection steps were carried out with DMF (5 × 
0.5min) and DCM (5 × 0.5 min) using 10 ml of solvent/g of resin each time. 
Protected amino acid (3 eq.), HBTU (3 eq.) and HOBt (3 eq.) in DMF (1–3 ml/g 
resin) were sequentially added to the resin and the mixture was irradiated in a 
Automated Microwave Peptide Synthesizer from Biotage AB (Initiator + 
Alstra™) for 20 min with a maximum temperature of 35 °C.  
The following protected N-methyl amino acids were then added stepwise: 
Fmoc-N-Me-Lys(Boc)-OH, Fmoc-N-Me-His(Trt)-OH, Fmoc-N-Me-Leu-OH, 
Fmoc-N-Me-Asp(OtBu)-OH, Fmoc-N-Me-Cys(Trt)-OH, Fmoc-N-Me-
Ser(tBu)-OH. 
Two treatments with piperidine/DMF (2: 8, v/v) for 10 min, and two extra 5-
min treatments with piperidine/DBU/toluene/DMF (5 : 5 : 20 : 70, v/v) were 
used. In addition, after each step of deprotection and after each coupling step, 
chloroanyl test was performed to confirm the complete removal of the Fmoc 
protecting group, respectively, and to verify that complete coupling has 
occurred on all the free amines on the resin. 
The N-terminal Fmoc group was removed and the peptides were acetylated as 
described above. Final peptides were cleaved from the resin with the following 
cleavage cocktails: TFA/DCM (95:5 v/v) for 90 min (10 ml/g resin). Peptides 
were precipitated by addition of cold diethyl ether, the solution was decanted, 
and the solid was triturated with cold diethyl ether, which was decanted again. 
This process was repeated twice (Scheme 3.2). 
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3.7.4 Synthesis of peptoids (compound 42-51) 
 
For on-resin assembling of Nκ-protected N-aminoalkylglycine residue, a 2 M 
solution of bromoacetic acid in DMF (10 equiv) and DIC (10 equiv) was added 
to the deprotected Rink resin (100–200 mesh, 1% DVB, 0.59 mmol/g). The 
acylation reactions and nucleophilic displacement were carried out under 
optimized reaction conditions: 60 bar, 70 °C, 0.15 mLmin-1 flow rate. After 
washing in DMF, a 1 M solution of the selected amine in DMF was added.  
The following protected amine were then added stepwise: Tert-butyl 4-
(aminomethyl)-1H-imidazole-1-carboxylate, N-Boc-1,4-butanediamine, 2-
(tert-butoxy)ethan-1-amine, Glycine tert-butyl ester hydrochloride, 2-Methyl-2-
propanethiol, 2-methylpropan-1-amine. 
Then the beads were washed with DMF and prepared for the formation of the 
next residue. Cleavage of peptides from the resin and removal of the acid labile 
protecting groups were simultaneously achieved by treatment of the final 
peptoid resin with a TFA-H2O-triisopropylsilane (TIS) mixture (95:2.5:2.5 by 
volume) for 90-120 min at room temperature. Peptides were precipitated by 
addition of cold diethyl ether and dried overnight under vacuum. Crude peptides 
were obtained in 70-80% yield. 
 
3.7.5 Purification and characterization  
 
All crude peptides were purified by RP-HPLC on a preparative C18-bonded 
silica column (Phenomenex Kinetex AXIA 100Å, 100 x 21.20mm, 5µm) using 
a Shimadzu SPD 20A UV/VIS detector, with detection at 210 and 254 nm. The 
column was perfused at a flow rate of 15 ml/min with solvent A (10%, v/v, 
water in 0.1% aqueous TFA), and a linear gradient from 10 to 90% of solvent B 
(80%, v/v, acetonitrile in 0.1% aqueous TFA) over 40 min was adopted for 
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peptide elution. Analytical purity and retention time (tr) of each peptide were 
determined using HPLC conditions in the above solvent system (solvents A and 
B) programmed at a flow rate of 1.500 ml/min using a linear gradient from 10 
to 90% B over 10 min, fitted with C-18 column Phenomenex, Aeris XB-C18 
column (150 mm х 4.60, 3.6µm). All analogues showed >97% purity when 
monitored at 215 nm. Homogeneous fractions, as established using analytical 
HPLC, were pooled and lyophilized. Peptides molecular weights were 
determined by ESI mass spectrometry and LC-MS in a LC-MS 2010 instrument 
fitted with Phenomenex, Aeris XB-C18 column (150 mm х 4.60, 3.6µm), eluted 
with a linear gradient from 10% to 90% B over 15 min, at a flow rate of 1.000 
mL/min. ESI-MS analysis in positive ion mode, were made using a Finnigan 
LCQ Deca ion trap instrument, manufactured by Thermo Finnigan (San Jose, 
CA, USA), equipped with the Excalibur software for processing the data 
acquired. The sample was dissolved in a mixture of water and methanol (50/50) 
and injected directly into the electrospray source, using a syringe pump, which 
maintains constant flow at 5 ml/min. The temperature of the capillary was set at 
220°C. 
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1 SKHSSLDCVLRP 9.73 1339.69 
4 KANEGLTWNSLKDK 9.56 1602.84 
5 TGSCAFDEFFSQSCAPGADPKSR 12.09 2407.01 
6 TNGESTADWAKN 6.19 1292.55 
7 GKNGKNCPDKFC 6.78 1309.58 
8 KSETKN 2.61 705.35 
9 NDNTECLAKLGGRPTYEE 9.78 2008.90 
10 NRKSSKHSSLDCVLRPTEGY 11.69 2276.12 
11 NRKSSKHSSLDCVLRP 11.13 1825.94 
12 SKHSSLDCVLRPTEGY 10.95 1790.85 
13 SLDCVLRP 4.48 942.48 
14 VLRP 3.67 524.33 
15 SLDC 3.13 477.17 
16 SKHSSLDC 4.63 916.39 
17 SKHS 2.33 498.24 
18 VLKP 3.17 496.32 
19 VLOP 3.06 482.36 
20 VLEP 3.56 497.27 
21 VLDP 3.51 483.25 
22 VLR 3.01 427.28 
23 LRP 3.06 425.26 
24 ALDC 3.27 461.18 
25 SADC 3.78 435.13 
26 SLAC 2.46 433.18 
27 SLDA 2.95 445.20 
28 AKHS 2.68 482.24 
29 SAHS 3.16 441.18 
30 SKAS 3.46 432.22 
31 SKHA 3.01 482.24 
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32 (N-Me)SLDC 2.71 491,56 
33 S(N-Me)LDC 2.81 491,56 
34 SL(N-Me)DC 2.73 491,56 
35 SLD(N-Me)C 2.79 491,56 
36 (N-Me)[SLDC] 3.01 533,64 
37 (N-Me)SKHS 3.13 512,56 
38 S(N-Me)KHS 3.16 512,56 
39 SK(N-Me)HS 3.16 512,56 
40 SKH(N-Me)S 3.08 512,56 
41 (N-Me)[SKHS] 3.41 554,64 
42 NhSerLeuAspCys 4.07 505,59 
43 SerNLeuAspCys 4.01 505,59 
44 SerLeuNAspCys 4.17 505,59 
45 SerLeuAspNhCys 4.27 505,59 
46 NhSerNLeuNAspNhCys 5.23 505,59 
47 NhSerLysHisSer 5.13 526,59 
48 SerNLysHisSer 5.16 526,59 
49 SerLysNHisSer 5.24 526,59 
50 SerLysHisNhSer 5.18 526,59 
51 NhSerNLysNHisNhSer 5.67 526,59 
a k’=[(peptide retention time-solvent retention time)/solvent retention time]. 
 
 
Figure 3.9 HPLC profile of pure peptide 1. 
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3.7.6 Biological assay 
 
3.7.6.1 Virus strains  
The following influenza A virus strains were used: A/RomaISS/02/08 H1N1 
(Brisbane-like) oseltamivir-sensitive virus, A/Parma/24/09 H1N1 (Brisbane-
like) oseltamivir-resistant virus, and A/Parma/05/06 H3N2 (Wisconsin-like). 
Virus titers were determined by a hemagglutinin titration and/or plaque assay 
according to the standard procedures.[58, 59] 
 
3.7.6.2 Cells 
Madin-Darby canine kidney (MDCK, ATCC, CRL-2936) cells were grown 
at 37°C in minimal essential medium (MEM, Invitrogen, Paisley, UK) 
containing 1.2 g/l NaHCO3, and supplemented with 10% inactivated fetal calf 
serum (FCS, Invitrogen, Paisley, UK), 2 mM glutamine, nonessential amino 
acids, penicillin (100 IU/ml), and streptomycin (100 μg/ml).   
 
3.7.6.3 Cytotoxicity assay 
This procedure was performed as reported elsewhere.[60] Briefly, two-fold 
serial dilutions of each protein in culture medium were incubated at 37°C with 
confluent MDCK cells grown in 96-well tissue culture microplates (Nalge Nunc 
Europe Ltd, Neerijse, Belgium). After 24 hours, cell morphology, viability, and 
proliferation were evaluated. Protein dilutions that did not affect any of these 
parameters were considered as non cytotoxic concentrations and utilized for 
antiviral assays. 
 
3.7.6.4 Hemagglutination inhibition assay (HI)  
Virus in PBS was incubated for 1 hour at 4uC with serial dilutions of bLf or 
peptidic fragments in PBS. An equal volume of 0.5% turkey erythrocytes was 
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then added and allowed to agglutinate. Titers were expressed as the reciprocal 
of the protein dilutions giving 50% hemagglutination of erythrocytes by four 
virus-agglutinating units. 
 
3.7.6.5 Neutralization assay  
Neutralization was carried out by incubating serial twofold peptide fragment 
dilutions, starting from 12.5 µM, in culture medium with equal volumes of virus 
suspension containing 106 p.f.u. for 1 hour at 4 °C. In negative controls, culture 
medium was used instead of peptide fragments in the same volume. MDCK 
cells, grown in 96-well tissue culture microplates (Nalge Nunc Europe Ltd, 
Neerijse, Belgium), were infected with 100 μl/well (10 p.f.u./cell; in 
quadruplicate) of the virus-peptide mixtures. After adsorption, cells were rinsed 
thoroughly and incubated at 37°C for 24 hours. The viral cytopathic effect 
(c.p.e.) was measured by neutral red staining.[61] 
 
3.7.7 NMR experiments and structure calculation 
 
The NMR sample of 1 was obtained dissolving 1 mg of the oligopeptide in 
50% of hexafluoroacetone and 50% of H2O (10 mM of KH2PO4) and placed in 
a 3 mm NMR tube (200 μl). The compound 17 (3.4 mg) was dissolved in 200 
μl of [D6] DMSO. 
All NMR experiments were performed on a Bruker DRX 600 spectrometer 
equipped with a cryoprobe at T = 300 K. All spectra were acquired in the phase-
sensitive mode, and the TPPI method was used for quadrature detection in the 
ω1 dimension.
[62] The residual water signal was suppressed by excitation 
sculpting with gradients. Data block sizes of 4096 in t2 and 512 equidistant t1 
values were used. Before Fourier transformation, the time domain data matrices 
were multiplied by shifted sine bell QSINE (SSB = 2) functions in both 
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dimensions. For 1, the DQF-COSY, 2D-TOCSY and 2D-NOESY experiments 
were executed with a number of 48 scans/t1 and a t1max value of 51.2 ms. For 17, 
the DQF-COSY, 2D-TOCSY and 2D-NOESY experiments were executed with 
16 scans/t1, 24 scans/t1 and 64 scans/t1, respectively, with a t1max value of 64.0 
ms. A mixing time of 80 ms was used for the 2D-TOCSY experiments. 2D-
NOESY and 2D-ROESY experiments were run with mixing times in the range 
of 100−550 ms. SPARKY software was used for qualitative and quantitative 
analyses of 2D spectra.[63] The obtained peak volumes were converted into 
upper distance bounds with the CALIBA routine from the CYANA software 
package. The pseudoatom corrections were applied for non-stereospecifically 
assigned protons of methylene and methyl groups. The experimentally derived 
constraints were used to generate an ensemble of 200 structures with the 
standard CYANA protocol of simulated annealing in the torsion angle space 
(using 50,000 steps). The best 20 structures that had low target function values 
and small residual violations were selected. All the 3D models were depicted 
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3.8 Supporting information 
 
Table S1. 1H chemical shifts (ppm) of peptide 1 in HFA/H2O (600 MHz, 300 K). 
Residue NH αH βH γH δH εH Others 
Ser1 7.83 4.12 3.63 - - - - 
Lys2 7.45 3.96 1.47 1.12 1.34 2.65 - 
   1.43 1.07    
His3 7.87 4.37 2.95 - 6.89 (2H) - - 
   2.84  8.08 (4H) - - 
Ser4 7.80 4.22 3.66 - - - - 
   3.54 - - - - 
Ser5 7.89 4.12 3.61     
Leu6 7.35 4.06 1.29 1.22 0.61 - - 
     0.51 - - 
Asp7 7.59 4.14 2.43 - - - - 
Cys8 7.40 4.06 2.69 - - - - 
   2.65     
Val9 7.25 3.76 1.81 0.61 - - - 
Leu10 7.31 3.99 1.30 1.22 0.53 - - 
     0.51   
Arg11 7.21 4.33 1.53 1.54 2.85  6.609 (NHE) 
   1.44  2.77  7.526 (NHZ) 
Pro12 - 4.04 1.93 1.61 3.39 - - 









Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 
- 82 - 
 
Table S2. 1H chemical shifts (ppm) of peptide 17 in [D6] DMSO (600 MHz, 300 K). 
Residue NH αH βH γH δH εH Others 
Acetyl - - - - - - 1.87 
Ser1 8.12 4.33 3.62 - - - - 
   3.57     
Lys2 8.34 4.17 1.65 1.27 1.51 2.73 - 
   1.51     
His3 8.06 4.41 2.96 - 6.82 (2H) 7.51 (4H) - 
   2.85     
Ser4 7.86 4.14 3.63 - - - - 
 
Table S3. Mean values of φ, ψ and χ1 angles and αC distances relative to the most 
representative conformers of peptide 1. 
Peptide Sequence 
i+1 i+2 αC distance 
φ ψ χ1 φ ψ χ1 i to i+2 i to i+3 
1 
Lys2- Ser5 -52.9 -29.7 -83.7 -138.1 -42.8 -140.3 - 4.8 
Ser4-Asp7 -76.3 166.1 -124.7 69.9 8.5 -67.0 - 6.2 
Leu6-Val9 -108.6 75.2 -95.6 64.6 27.2 -120.6 - 5.7 
Asp7-Leu10 64.6 27.2 -120.6 71.1 42.9 -164.2 - 5.3 
Val9-Arg11 -76.1 91.0 -147.5 - - - 5.9 - 
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Figure S1. 2D-NOESY spectrum of peptide 1 HFA/H2Osolution (600 MHz, 300 K, 
tmix = 400 ms). 
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Figure S2. NOE connectivities from 2D-NOESY spectra of peptide 1 in HFA/H2O 
(600 MHz, 300 K, tmix = 400 ms). 
 
 
Figure S3. Ramachandran plot of NMR derived bundle of peptide 1, calculated by 
PROCHECK1 software. 
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Figure S4. HPLC profile of crude peptide 32 synthesized at room temperature. 
 
 
Figure S5. HPLC profile of crude peptide 32 synthesized using microwave. 
 
Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 
- 86 - 
 
 



















Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 




[1] Ammendolia, M. G.; Agamennone, M.; Pietrantoni, A.; Lannutti, F.; 
Siciliano, R. A.; De Giulio, B.; Amici, C.; Superti, F. Bovine lactoferrin-derived 
peptides as novel broad-spectrum inhibitors of influenza virus. Pathog. Glob. 
Health. 2012, 106, 12-19. 
 
[2] Superti, F. E. D.; Agamennone, M.; Ammendolia, M. G.; Pietrantoni, 
A.; Lannutti, F.  Lactoferrin derived peptides for use as broad-spectrum 
inhibitors of Influenza virus infection. WO2013072946, 2014; Istituto 
Superiore Di Sanità, Università Degli Studi "G. D'annunzio" (IT). 
 
[3] Manavalan, P.; Momany, F. A. Conformational Energy Studies on N-
Methylated Analogues of Thyrotropin Releasing Hormone, Enkephalin and 
Luteinizing Hormone Releasing Hormone. Biochemistry. 1980, 19, 1943-1973. 
[4] Tonelli, A. E. The Effects of Isolated N-Methylated Residues on the 
Conformational Characteristics of Polypeptides. Biopolymers. 1976, 15, 1615-
1622.  
 
[5] Ron, D.; Gilon, C.; Hanani, M.; Vromen, A.; Selinger, Z.; Chorev, M. 
N-Methylated Analogues of Ac[Nle28,31]CCK(26-33). J. Med. Chem. 1992, 
35, 2806-2811. 
 
[6] Haviv, F.; Fitzpatrick, T. D.; Swenson, R.E.; Nichols, C. J.; Mort, N. A.; 
Bush, E. N.; Diaz, G.; Bammert, G.; Nguyen, A.; Rhutasel, N. S.; Nellans, H. 
N.; Hoffman, D. J.; Johnson, E. S.; Greer, J. Effect of N-methyl substitution of 
the peptidebonds in luteinizing hormone-releasing hormone agonists. J. Med. 
Chem. 1993, 36, 363–369. 
 
[7] Cody, W. L.; He, J. X.; Reily, M. D.; Haleen, S. J.; Walker, D. M.; 
Reyner, E. L.; Stewart, B. H.; Doherty, A. M. Design of a potent combined 
pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg(16)-
Leu-Asp-Ile-[NMe]Ile- Trp(21) (PD 156252): examination of 
itspharmacokinetic and spectralproperties. J. Med. Chem. 1997, 40, 2228–2240. 
 
[8] Bach, A. C.; Espina, J. R.; Jackson, S. A.; Stouten, P. F. W.; Duke, J. L.; 
Mousa, S. A.; De Grado,W. F. Type II to type I beta-turn swap changes 
specificity for integrins. J. Am. Chem. Soc. 1996, 118, 293–294. 
 
[9] Pierson, M. E.; Comstock, J. M.; Simmons, R. D.; Kaiser, F.; Julien, R.; 
Zongrone, J.; Rosamond, J. D. Synthesis and biological evaluation of potent, 
Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 
- 88 - 
 
selective, hexapeptide CCK-A agonist anorectic agents. J. Med. Chem. 1997, 
40, 4302–4307.  
 
[10] Rajeswaran, W. G.; Hocart, S. J.; Murphy, W. A.; Taylor, J. E.; Coy, D. 
H. Highly potent and subtype selective ligands derived by N-methyl scan of a 
somatostatin antagonist. J. Med. Chem. 2001, 44, 1305–1311. 
 
[11] Laufer, R.; Wormser, U.; Friedman, Z. Y.; Gilon, C.; Chorev, M.; 
Selinger, Z. Neurokinin-B is a preferred agonist for a neuronal substance- P 
receptor and its action is antagonized by enkephalin. Proc. Natl. Acad. Sci. USA. 
1985, 82, 7444–7448. 
 
[12] Samanen, J.; Ali, F.; Romoff, T.; Calvo, R.; Sorenson, E.; Vasko, J.; 
Storer, B.; Berry, D.; Bennett, D.; Strohsacker, M.; Powers, D.; Stadel, J.; 
Nichols, A. Development of a small RGD peptide fibrinogen receptor antagonist 
with potent antiaggregatory activity in vitro. J. Med. Chem. 1991, 34, 3114–
3125.  
 
[13] Dechantsreiter, M. A.; Planker, E.; Mathä, B.; Lohof, E.; Hölzemann, 
G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-methylated cyclic RGD 
peptides as highly active and selective αvβ3 integrin antagonists. J. Med. Chem. 
1999, 42, 3033–3040. 
 
[14] Barker, P. L.; Bullens, S.; Bunting, S.; Burdick, D. J.; Chan, K. S.; 
Deisher, T.; Eigenbrot, C.; Gadek, T. R.; Gantzos, R.; Lipari, M. T.; Muir, C. 
D.; Napier, M. A.; Pitti, R. M.; Padua, A.; Quan, C.; Stanley, M.; Struble, M.; 
Tom, J. Y. K.; Burnier, J. P. Cyclic RGD peptide analogs as antiplatelet 
antithrombotics. J. Med. Chem. 1992, 35, 2040–2048. 
 
[15] Wipf, P. Synthetic studies of biologically active marine cyclopeptides. 
Chem. Rev. 1995, 95, 2115–2134.  
 
[16] Romero, F.; Espliego, F.; Pérez Baz, J.; García de Quesada, T.; Gravalos, 
D.; De la Calle, F.; Fernández-Puentes, J. L. Thiocoraline, a new depsipeptide 
with antitumor activity produced by a marine micromonospora. I. Taxonomy, 
fermentation, isolation, and biological activities. J. Antibiot. 1997, 50, 734–737. 
 
[17] Soto, P.; Griffin, M. A.; Shea, J. E. New insights into the mechanism of 
alzheimer amyloid-β fibrillogenesis inhibition by N-methylated peptides. 
Biophys. J. 2007, 93, 3015–3025. 
 
Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 
- 89 - 
 
[18] Conradi, R. A.; Hilgers, A. R.; Ho, N. F. H.; Burton, P. S. The influence 
of peptide structure on transport across caco-2 cells. II. Peptide-bond 
modification which results in improved permeability. Pharm. Res. 1992, 9, 435–
439. 
 
[19] Sagan, S.; Karoyan, P.; Lequin, O.; Chassaing, G.; Lavielle, S. N- and 
Cα-methylation in biologically active peptides: synthesis, structural and 
functional aspects. Curr. Med. Chem. 2004, 11, 2799–2822. 
 
[20] Zuckermann, R. N.; Kerr, J. M.; Kent, S. B. H.; Moos, W. H. Efficient 
method for the preparation of peptoids [oligo(N-substituted glycines)] by 
submonomer solid-phase synthesis. J. Am. Chem. Soc. 1992, 114, 10646-10647.   
 
[21] Miller, S. M.; Simon, R. J.; Ng, S.; Zuckermann, R. N.; Kerr J. M.; 
Moos, W. H. Comparison of the proteolytic susceptibilities of homologous L-
amino acid, D-amino acid, and N-substituted glycine peptide and peptoid 
oligomers. Drug Dev. Res. 1995, 35, 20–32. 
 
[22] Sanborn, T. J.; Wu, C. W.; Zuckermann, R. N.; Barron, A. E. Extreme 
stability of helices formed by water-soluble poly-N-substituted glycines 
(polypeptoids) with α-chiral side chains. Biopolymers. 2002, 63, 12-20. 
 
[23] Figliozzi, G. M.; Goldsmith, R.; Ng, S. C.; Banville, S. C.; Zuckermann, 
R. N. Synthesis of Nsubstituted glycine peptoid libraries. Methods Enzymol. 
1996, 267, 437-447.  
 
[24] Patch, J. A.; Kirshenbaum, K.; Seurynck, S. L.; Zuckermann, R. N.; 
Barron, A. E. Versatile Oligo(N-Subsitituted) Glycines: The Many Roles of 
Peptoids in Drug Discovery. In Pseudopeptides in Drug Discovery; Nielsen, 
P.E., Ed.; Wiley-VCH Verlag, GmbH & Co. KgaA: Weinheim, Germany. 2004, 
1-31. 
 
[25] Richter, L. S.; Spellmeyer, D. C.; Martin, E. J.; Figliozzi, G. M.; 
Zuckermann, R. N. Automated Synthesis of Nonnatural Oligomer Libraries: 
The Peptoid Concept. In Combinatorial Peptide and Nonpeptide Libraries; Jung, 
G., Ed.; VCH: Weinheim, Germany. 1996, 387-404.  
 
[26] Zuckermann R. N.; Kodadek T. Peptoids as potential therapeutics. Curr. 
Opin. Mol. Therap. 2009, 11, 299-307.  
 
Chapter III: Lactoferrin-derived Peptides Active towards Influenza: Identification of 
Three Potent Tetrapeptide Inhibitors 
 
- 90 - 
 
[27] Miller, S. M.; Simon, R. J.; Ng, S.; Zuckermann, R. N.; Kerr, J. M.; 
Moos, W. H. Proteolytic studies of homologous peptide and N-substituted 
glycine peptoid oligomers. Bioorg. Med. Chem. Lett. 1994, 4, 2657-2662.  
 
[28] Lim, H. S.; Muralidhar Reddy, M.; Xiao, X.; Wilson, J.; Wilson, R.; 
Connell, S.; Kodadek, T. Rapid identification of improved protein ligands using 
peptoid microarrays. Bioorg. Med. Chem. Lett. 2009, 19, 3866-3869. 
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Abstract 
The preparation of lactam constrained cyclic peptide requires orthogonal 
protecting groups for side-chain amino and carboxylate functionalities involved 
in the cyclization process.  
In this study, starting from the synthesis of a lactam peptide, H-Ser-[Lys-His-
Ser-Ser-Leu-Asp]-Cys-Val-Leu-Arg-Pro-NH2, we report the identification of 
problematic stretches during the sequence assembly process. Sequence 
elongation was achieved with standard Fmoc peptide synthesis and an α-allyl-
protected aspartic acid residue was then coupled to the growing chain in order 
to allow the cyclization. Surprisingly, after the deprotection of aspartic acid 
Fmoc group, the formation of a mixture of desired compound, aspartimide and 
piperidinyl derivative was observed. Therefore, we studied this problem and 
described its resolution using β-2-phenylisopropyl ester as β-protecting group 
of aspartic acid. 
 
Keywords 
Cyclic peptide, aspartimide, allyl ester, side reactions. 
 
Abbreviations 
Abbreviations used for amino acids and designation of peptides follow the rules 
of the IUPAC-IUB Commission of Biochemical Nomenclature in J. Biol. Chem. 
1972, 247, 977-983. Amino acid symbols denote L-configuration unless 
indicated otherwise. The following additional abbreviations are used: HOBt, N-
hydroxy-benzotriazole; HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluoro-phosphate; HOAt, 1-Hydroxy-7-
azabenzotriazole; DIEA, N,N-diisopropylethyl-amine; DMF, N,N-
dimethylformamide; DCM, dichloromethane; NMP, N-Methyl-2-pyrrolidone; 
TIS, triisopropylsilane; TFA, trifluoroacetic acid; Boc, tert-butoxycarbonyl; 
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ESI-MS, electro spray ionization mass spectrometry; Fmoc, 





Cyclic peptides, in contrast to linear peptides, have been considered to have 
greater potential as therapeutic agents due to their increased chemical and 
enzymatic stability, more defined structure, and improved pharmacodynamic 
properties.[1, 2] Specially, side-chain lactam bridges linking amino acid residues 
that are spaced several residues apart in the linear sequence offer a convenient 
and flexible method for introducing conformational constraints into a peptide 
structure.  
Solid phase peptide synthesis (SPPS) is the most convenient approach to 
prepare lactam constrained cyclic peptides. In particular, the preparation of 
these peptides generally require a pair of selectively cleavable protecting groups 
used for protection of the amine and carboxylic acid to be linked by solid-phase 
cyclization. Among these groups, the most used is the Allyl ester (OAll) for side 
chain carboxilyc acids, along with its urethane-based partner for side-chain 
amines, the allyloxycarbonyl group (Alloc). OAll-protecting group, stable to 
both acid and base, is reliably cleaved in good yield on solid supports using the 
Pd(0) catalyst.[3-5] Nevertheless side reactions can hamper the overall synthesis 
leading to decreased yields and/or quality. 
In particular, aspartimide (Asi) formation, a well-documented side reaction 
when allyl ester is used as a protection for the aspartic acid side chain, can be 
observed. Its formation, which can either be acid or base catalyzed, occurs while 
the piperidine-catalyzed Fmoc cleavage of peptides containing aspartic      
acid.[6-9] 
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The propensity of aspartimide formation mainly depends on the aspartate 
carboxyl neighboring residue.[10, 11] 
As a matter of fact, aspartimide is the result of an attack of an amidate species 
at the carbonyl carbon of the side chain carboxylate of aspartic acid. Subsequent 
hydrolysis of the aspartimide ring gives rise to a mixture of α- and β-aspartyl 
peptides. In addition, nucleophilic attack of the imide ring by piperidine results 




Figure 4.1 Mechanism for aspartimide-related by-product formation. 
 
In recent years several strategies to avoid Asi formation have been 
developed.[2] Nevertheless, employing of these methods does not fully prevent 
Asi formation and may cause certain difficulties during synthesis, or may not be 
suitable for the ‘on-resin’ synthesis of cyclic or branched peptides.  
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In this work, we tried to stabilize of 3D structure of bLf C-lobe fragment 
418-429 through cyclization of the peptide backbone, H-Ser-[Lys-His-Ser-Ser-
Leu-Asp]-Cys-Val-Leu-Arg-Pro-NH2 (Figure 4.2). Sequence elongation was 
achieved with standard Fmoc peptide synthesis and an α-allyl-protected 
aspartic acid residue was then coupled to the growing chain in order to allow 
the cyclization. During the synthesis of this peptide, unfortunately, the major 
product obtained showed a mass difference of +67 Da respect to expected 
cyclic peptide.  
 
 
Figure 4.2 Stucture of peptide 71. 
 
Therefore, the synthesis and the gradual elongation of this peptide were 
monitored. The formation of side products was observed after the deprotection 
of the Fmoc group of aspartic acid. 
In particular, after the deprotection of aspartic acid Fmoc group by piperidine 
(25% v/v in DMF) for 30 min at room temperature, we observed a  removal of 
Asp allyl group. LC-MS analysis revealed a mixture of three compounds 
(Figure 4.3): desired compound (52), aspartimide (Asi, 53) and 4-(1-
Piperidinyl) aspartate derivative (54) (Table 4.1). 
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NMR analysis in DMSOd6 solution clearly demonstrated the presence of 
piperidinyl (pyp) derivative. 
 
 
Figure 4.4 Partial NOESY spectrum of compound 54. 
 
In the present study, we report the problem of Asi formation during Fmoc-
based SPPS of peptide containing a lactam bridge using Allyl group to protect 
β-carboxy side-chain group of Asp residue. 
Starting from these observations, during my PhD, I intended to identify the 
factors affecting Asi formation and thus to find a simple and efficient synthesis 
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4.2.1 Synthesis of peptides 
 
The synthesis of peptides (52-71) was performed according to the solid phase 
approach using standard Fmoc methodology in a manual reaction vessel.[12] 
Different resins were used: Rink-Amide, Fmoc-PAL-PEG-PG and 2-
chlorotrityl chloride resin. Rink-Amide and Fmoc-PAL-PEG-PG were 
deprotected by a 25% piperidine solution in N, N-dimethylformamide (DMF) 
for 30 min and the first amino acid was linked onto the resin. 
For 2-chlorotrityl chloride resin, the first Nα-Fmoc amino acid and DIPEA were 
dissolved in dry dichloromethane containing, if necessary, a small amount of 
dry DMF. This was added to the resin and stirred for 30-120 min.  
The following protected amino acids were then added stepwise. Each coupling 
reaction was accomplished using a 3-fold excess of amino acid with HBTU and 
HOBt in the presence of DIPEA. The Nα-Fmoc protecting groups was removed 
by treating the protected peptide resin with a 25% solution of piperidine in 
DMF.  
In addition, after each step of deprotection and after each coupling step, Kaiser 
test was performed to confirm the complete removal of the Fmoc protecting 
group, respectively, and to verify that complete coupling has occurred on all the 
free amines on the resin. [13] 
The preparation of cyclic peptides, through a side-chain-to-side-chain 
cyclization, was carried out after removal of the 2-PhiPr/Mmt protection with 
1% TFA/DCM. 
The N-terminal Fmoc group was removed as described above. Finally, the 
peptides were released from the resin with trifluoroacetic acid (TFA)/ 
triisopropylsilane (iPr3SiH) / H2O (90:5:5) for 3 h. The resin was removed by 
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filtration, and the crude peptide was recovered by precipitation with cold 
anhydrous ethyl ether to give a white powder and then lyophilized (Scheme 4.1). 
 
The crude peptides were purified by preparative RP-HPLC. Analytical HPLC 
indicated the degree of purity of the peptides and molecular weights were 
confirmed by ESI-MS. 
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Scheme 4.1 Synthesis and folding of peptide 71. 
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4.3 Results and discussion 
 
The preparation of the lactam peptide mentioned above requires orthogonal 
protecting groups for side-chain amino and carboxylate functionalities.[2, 14] Use 
of the allyl ester (OAll) group for this role in the protection of the aspartic acid 
side-chain resulted in the formation of unexpected side-products. [15, 16] 
To study this phenomenon and try to get the desired sequence in a good yield 
we used different approaches. We study the influence of resins, protecting 
groups, bases and  amino acid sequence on the formation of byproducts. 
To simulate deprotection conditions of prolonged synthesis, all peptides were 
incubated with piperidine (25%v/v in DMF) for 30 min, 1h, 2h, 3h, 6h, 12h and 
16h.  
 
4.3.1 Factors influencing aspartimide formation 
 
4.3.1.1 Solid support (peptides 52, 55 and 56) 
It has been observed that the resin/linker used as a solid support in solid phase 
synthesis may sometimes contribute to decreasing the formation of aspartimide. 
Therefore, to compare the extent of side reactions formation and factors that can 
affect it, we studied the effect of the polymer support. 
As a first resin we used a Rink Amide, a resin that releases amides rather than 
carboxylic acids, as required by the peptide sequence. This is a resin acid labile, 
thus the solution used for the cleavage of the peptide from the resin is at 90% of 
TFA in DCM. The synthesis did not have successful leading to the formation of 
the already mentioned side products.  
Albericio et al. used the hydrophilic resins.[17] The most commonly used are 
resins, polystyrene-based always, on which are grafted chains of polyethylene 
glycol (PEG). These chains move away from the functional groups of the resin 
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core for which the reaction conditions become more "solution-like". Therefore, 
we used the resin Fmoc-PAL-PEG-PS (Peptide Amide Linker-polyethylene 
glycol-polystyrene) to avoid the problems caused steric hindrance. In the 
literature, however, it is reported that the use of 2-chlorotrityl chloride resin, 
which offers the possibility of mild acidolysis of the peptide chain, prevents this 
undesired cyclization.[18, 19] 
Therefore, although it is used to acids peptides, we used this resin for the 
synthesis of our peptide to evaluate their effectiveness.  
Both approaches have not been successful (Table 4.2). 
 
























4.3.1.2 Base (peptides 52, 57-59)  
Piperidine, the standard secondary amine applied in the removal of Fmoc in 
solid-phase, gives rise to a considerably high percentage of Aspartimide, plus 
the additional presence of piperidides of the α- and β-peptide.[20] The 
concentration of the secondary amine also affects the amount and ratio of 
byproducts.[21, 22] We replaced the piperidine (pKa=11.12) with the milder base 
piperazine (pKa = 9.73) and morfoline (pKa = 8.3), that could reduce 
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aspartimide formation, however, at the cost of the reaction rate. It did not show 
a significant effect.  
N-hydroxylamine-based compounds and coupling reagents are widely used 
as amide bond-forming agents.[23-27] In addition, additives are beneficial in order 
to reduce the extent of racemization and guanidylation of the N-terminus of the 
growing peptide chain and to increase coupling efficiency.[28, 29] This substantial 
contribution to coupling strategies prompted their evaluation in the prevention 
of other non-coupling-derived side reactions. It was showed indeed that, in 
unwanted reactions, their addition can be advantageous. N-Hydroxylamine-
based additives also contribute to the wide arsenal of approaches to prevent the 
formation of Asi and derived byproducts. This beneficial effect is observed in 
base-catalyzed Asi cyclization, during coupling or Fmoc removal with 
secondary/tertiary amines. It is proposed that the unique acidic properties of N-
hydroxylamines used as additives in peptide synthesis (pKa = 2-10) are 
responsible for this behaviour.[30] The abstraction of the amide backbone proton 
is  the crucial step in the cyclization that leads to Asi. Thus, addition of a relative 
strong acid, such as HOBt, results in competition with the Asp-X amide 
backbone for the base present in the medium.[30] When HOBt is used as additive, 
conversion into its anion by the effect of the base would decrease the percentage 
of negatively charged amide backbone nitrogen, which is responsible for 
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Figure 4.5 Competition between N-hydroxylamine and amide backbone proton 
abstraction. 
 
Consequently, we studied the suppression of aspartimide formation by 
adding small amounts of organic acids to the deprotection agent piperidine. 
However, under these conditions, treatment with piperidine containing 0.1 M of 
HOBt caused the complete formation of aspartimide and piperidinyl derivate. 
 







(16 h) base treatment 
By-products (%) 
52 All Piperidine 
 
100 
57 All Morfoline 
 
100 





HOBt 0.1 M   +   
100 
 
4.3.1.3 β-carboxyl protecting group (peptides 52, 60, 61) 
The nature of the β-carboxyl ester, acting as protecting group, markedly 
influences on the impact of the aspartimide side reaction.  
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Figure 4.6 Structures of Asp β-carboxyl protecting groups used. 
 
Initially, we used Asp(OAll) as protecting group of aspartic acid, but it gives 
rise to high percentages of aspartimide peptide and thus offers the poorest 
protection against this unwanted process. In order to minimize the nucleophilic 
attack of the preceding amide backbone nitrogen atom to Asp, ODmab [4-{N-
[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino}benzyl], 
highly sterically hindered β-protecting group, was used. However, the β-
protection of Asp as ODmab does not result in improved prevention of the side 
reaction and is comparable to that achieved by β-allyl ester protection. 
Protection with the bulky tert-butyl ester has shown greater efficacy than the 
abovementioned strategies in preventing this side reaction in basic media.[10, 19, 
32] In fact, in classical Fmoc removal conditions, it not give rise to conversion 
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(16 h) base treatment 
α- β-piperidinyl peptide (%) 
52 All 100 
60 Dmab 100 
61 tBu - 
 
4.3.1.4 Sequence 
Undoubtedly, the nature of the neighbouring amino acid located at the C-
terminus of the aspartic acid (Asp-X) and the amino acidic sequence determine 
the degree of aspartimide formation, since the cyclization of Asp to Asi is 
initiated by attack of the amide backbone nitrogen of the preceding residue.[22] 
Two different approaches were used to evaluate the influence of amino acids β-
functional groups on aspartimide formation: i) L-Ala scanning analysis of 
peptide 52 (peptides 62-66); ii) scramble peptides (peptides 67-69). 
 
Alanine scanning approach (peptides 62-66) 
We decided to check the relevance of side chains of each aminoacidic residue 
in side products formation through L-Ala scanning analysis (peptides 62-66, 
Table 4.5). These changes did not show a significant effect to suppress 
aspartimide formation. 
 





(16 h) base treatment 
α- β-piperidinyl peptide (%) 
62 All DCVLRA 100 
63 All DCVLAP 100 
64 All DCVARP 100 
65 All DCALRP 100 
66 All DAVLRP 100 
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Scramble peptide (peptides 67-69) 
Finally, the scramble analogue peptides, constructed through permutation of 
the original peptide sequence, were synthesized to examine the sequence 
dependence on Asi and piperidide formation. These side-products were not 
observed in scramble peptides. 
Therefore, we hypothesized that the conversion of Asp into Asi units could be 
conformation-dependent. 
 





(16 h) base treatment 
α- β-piperidinyl peptide (%) 
67 All DLPRVC - 
68 All DVRPCL - 
69 All DPCVLR - 
 
4.3.2 β-(2-phenylisopropyl) ester to minimization of aspartimide formation 
 
Finally, in order to minimize the nucleophilic attack of the preceding amide 
backbone nitrogen atom to Asp, we used highly sterically hindered β-protecting 
group, as Asp [OPhiPr = β-(2-phenylisopropyl)]. An orthogonal protecting 
groups for side-chain of cysteine was used. 
In peptide 70, we used Asp(2-PhiPr) and Cys(tBu), it does not suppress the 
aspartimide formation.  
Moreover, in order to evaluate the influence of high bulkiness of trityl, β-
protecting group of cysteine, we synthetized peptide 71. It results in increased 
prevention of Asi. 
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Figure 4.7 Influence of cysteine β-protecting group on aspartimide formation.  
 






(16 h) base treatment 
α- β-piperidinyl peptide (%) 
70 
2-PhiPr 
tBu  100 




The synthesis of lactam constrained cyclic peptide requires orthogonal 
protecting groups for side-chain amino and carboxylate functionalities. To 
synthesize a cyclic peptide, H-Ser[Lys-His-Ser-Ser-Leu-Asp]-Cys-Val-Leu-
Arg-Pro-NH2, we used the allyl ester (OAll) group for this role in the protection 
of the aspartic acid side-chain.  
Surprisingly, our approach to synthesize the peptide mentioned above, failed 
completely. In particular, after the deprotection of aspartic acid Fmoc group by 
piperidine (20% v/v in DMF) for 30 min at room temperature, the formation of 
unexpected side-products was observed. 
Therefore, we studied this phenomenon and tried to obtain the desidered 
sequence with different approaches. We hypothesized that the aspartimide and 
piperidinyl derivative formation is conformation-dependent. 
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Finally, we synthetized the desidered peptide, using as β-protecting group of 
aspartic acid and lysine, β-2-phenylisopropyl ester and methoxytrityl, 
respectively. LC-MS analysis confirmed the presence of the desired cyclic 
peptide. 
 
4.5 Experimental section 
 
Nα-Fmoc-protected amino acids, Rink amide-resin, Fmoc-PAL-PEG-PS resin, 
2-Chlorotrityl-cloride resin, N-hydroxy-benzotriazole (HOBt), 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-phosphate 
(HBTU), N,N-diisopropylethyl-amine (DIPEA), piperidine, morpholine, 
piperazine and Trifluoroacetic acid were purchased from Iris Biotech 
(Germany). Peptide synthesis solvents, reagents, as well as CH3CN for high 
performance liquid chromatography (HPLC) were reagent grade and were 
acquired from commercial sources and used without further purification unless 
otherwise noted. 
 
4.5.1 Synthesis of peptides with Rink-Amide and Fmoc-PAL-PEG-PS resin 
 
The synthesis of peptides (52-55, 57-71) was performed according to the 
solid phase approach using standard Fmoc methodology in a manual reaction 
vessel.[33, 34] 
The first amino acid, Nα-Fmoc-Xaa-OH (Xaa = Pro, Cys(Trt), Arg(Pbf), Leu, 
Ala), was linked on to the Rink resin (100–200 mesh, 1% DVB, 0.59 mmol/g) 
and Fmoc-PAL-PEG-PS resin (100–200 mesh, 1% DVB, 0.22 mmol/g) 
previously deprotected by a 25% piperidine solution in N, N-
dimethylformamide (DMF) for 30 min.  
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The following protected amino acids were then added stepwise: Nα-Fmoc-Pro-
OH, Nα-Fmoc-Arg(Pbf)-OH, Nα-Fmoc-Leu-OH, Nα-Fmoc-Val-OH, Nα-Fmoc-
Cys(Trt)-OH, Nα-Fmoc-Cys(tBu)-OH, Nα-Fmoc-Asp(OtBu)-OH, Nα-Fmoc-
Ala-OH, Nα-Fmoc-Asp(OAll)-OH, Nα-Fmoc-Asp(OtBu)-OH, Nα-Fmoc-
Asp(ODmab)-OH, Nα-Fmoc-Asp(2-PhiPr)-OH. 
Each coupling reaction was accomplished using a 3-fold excess of amino acid 
with HBTU and HOBt in the presence of DIPEA (6 eq.). The Nα-Fmoc 
protecting groups were removed by treating the protected peptide resin with a 
25% solution of piperidine in DMF (1 × 5 min and 1 × 25 min). The peptide 
resin was washed three times with DMF, and the next coupling step was initiated 
in a stepwise manner. The peptide resin was washed with DCM (3×), DMF (3×), 
and DCM (3×), and the deprotection protocol was repeated after each coupling 
step. In addition, after each step of deprotection and after each coupling step, 
Kaiser test was performed to confirm the complete removal of the Fmoc 
protecting group, respectively, and to verify that complete coupling has 
occurred on all the free amines on the resin.  
 
4.5.2 Synthesis of peptides 56 with 2-Chlorotrityl-cloride resin 
 
The peptides 56 was synthetized using a 2-chlorotrityl chloride resin. The 
first Nα-Fmoc-Pro-OH, (0.6-1.2 equiv relative to the resin for 2-chlorotrityl 
resin) and DIPEA (4 equiv relative to amino acid) were dissolved in dry 
dichloromethane (DCM) (approx. 10 mL per gram of resin) containing, if 
necessary, a small amount of dry DMF (enough to facilitate dissolution of the 
acid). This was added to the resin and stirred for 30-120 min. After stirring, the 
resin was washed with 3×DCM/MeOH/DIPEA (17:2:1), 3×DCM, 2×DMF and 
2×DCM. Other Nα-Fmoc amino acids (4 equiv) were sequentially coupled as 
previously described.  
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4.5.3 Synthesis of lactam peptide (peptide 71) 
 
The corresponding linear peptide was synthetized as described above and the 
amino acids Nα-Fmoc-Asp(2-PhiPr)-OH and Nα-Fmoc-Lys(Mmt)-OH were 
used as lactam precursors. After linear assembly, the 2-PhiPr and the Mmt 
groups were removed according to the following procedure: 200 mg of peptide 
resin was washed with dichloromethane (DCM) and a solution of 1% 
TFA/DCM was added. The reaction was allowed to proceed for 30 min. The 
peptide resin was washed with DCM (3x), DMF (3x) and DCM (4x). The 
macrocyclic lactam ring formation was mediated by addition of HBTU (6 
equiv), HOBt (6 equiv) and DIPEA (12 equiv) under Ar for 2 h. The process 
was repeated if necessary (Kaiser test used to monitor completion).  
The N-terminal Fmoc group was removed as described above. Finally the 
peptides were released from the resin with TFA/TIS/H2O (90:5:5) for 3 h. The 
resin was removed by filtration, and the crude peptide was recovered by 
precipitation with cold anhydrous ethyl ether to give a white powder and then 
lyophilized. 
 
4.5.4 Purification and characterization  
 
All crude peptides were purified by RP-HPLC on a preparative C18-bonded 
silica column (Phenomenex Kinetex AXIA 100Å, 100 x 21.20mm, 5µm) using 
a Shimadzu SPD 20A UV/VIS detector, with detection at 210 and 254 nm. The 
column was perfused at a flow rate of 15 ml/min with solvent A (10%, v/v, 
water in 0.1% aqueous TFA), and a linear gradient from 10 to 90% of solvent B 
(80%, v/v, acetonitrile in 0.1% aqueous TFA) over 40 min was adopted for 
peptide elution. Analytical purity and retention time (tr) of each peptide were 
determined using HPLC conditions in the above solvent system (solvents A and 
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B) programmed at a flow rate of 1.500 ml/min using a linear gradient from 10 
to 90% B over 11 min, fitted with C-18 column Phenomenex, Aeris XB-C18 
column (150 mm х 4.60, 3.6µm). All analogues showed >97% purity when 
monitored at 215 nm. Homogeneous fractions, as established using analytical 
HPLC, were pooled and lyophilized. Peptides molecular weights were 
determined by ESI mass spectrometry and LC-MS in a LC-MS 2010 instrument 
fitted with Phenomenex, Aeris XB-C18 column (150 mm х 4.60, 3.6µm), eluted 
with a linear gradient from 10% to 60% B over 15 min, at a flow rate of 1.000 
mL/min. ESI-MS analysis in positive ion mode, were made using a Finnigan 
LCQ Deca ion trap instrument, manufactured by Thermo Finnigan (San Jose, 
CA, USA), equipped with the Excalibur software for processing the data 
acquired. The sample was dissolved in a mixture of water and methanol (50/50) 
and injected directly into the electrospray source, using a syringe pump, which 
maintains constant flow at 5 ml/min. The temperature of the capillary was set at 
220°C. 
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52 9.93 740.91 
53 9.67 697.85 
54 6.72 767.98 
55 9.93 740.91 
56 9.96 741.90 
57 10.26 769.96 
58 10.21 768.97 
59 6.72 767.98 
60 9.81 700.85 
61 6.72 767.98 
62 9.97 741.95 
63 9.23 682.87 
64 9.89 725.90 
65 9.91 739.93 
66 9.90 735.92 
67 9.95 740.93 
68 9.96 740.95 
69 9.92 740.89 
70 6.72 767.91 
71 12.31 1321.54 
a k’=[(peptide retention time-solvent retention time)/solvent retention time]. 
 
 
Figure 4.8 HPLC profile of pure piperidinyl derivative. 
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The present study describes the identification of three C-lobe bLf-derived 
tetrapeptides as the minimum fragments expressing the broad anti-influenza 
activity of bLf. Peptides 14 (VLRP), 15 (SLDC), and 17 (SKHS) were designed 
from the fragment 418-429 (1, SKHSSLDCVLRP), which is involved in the C-
lobe bLf-HA interaction. These tetrapeptides retain the inhibitory potency of 
the fragment 418-429 and inhibit the influenza virus hemagglutination and cell 
infection in a concentration range of femto- to picomolar. NMR spectroscopy 
analysis performed on compounds 1 showed a global turn conformation for this 
peptide and hypothesized the preferred bioactive conformation of our 
tetrapeptides. Our results strongly encourage the pursuit of this path for the 
development of a novel class of anti-influenza drugs. 
Moreover, based on conformational analysis, we tried to stabilize 3D 
structure of fragment 418-429, SKHSSLDCVLRP, through cyclization of the 
peptide backbone. 
The synthesis of lactam constrained cyclic peptide requires orthogonal 
protecting groups for side-chain amino and carboxylate functionalities. To 
synthesize this peptide, we used the allyl ester (OAll) group for this role in the 
protection of the aspartic acid side-chain.  
Surprisingly, our approach to synthesize the peptide mentioned above, failed 
completely. In particular, after the deprotection of aspartic acid Fmoc group by 
piperidine (20% v/v in DMF) for 30 min at room temperature, the formation of 
unexpected side-products was observed. 
Therefore, we studied this phenomenon and tried to obtain the desidered 
sequence with different approaches. We hypothesized that the aspartimide and 
piperidinyl derivative formation is conformation-dependent. 
Conclusions 
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Finally, we synthetized the desidered peptide, using as β-protecting group of 
aspartic acid and lysine, β-2-phenylisopropyl ester and methoxytrityl, 
respectively. LC-MS analysis confirmed the presence of the desired cyclic 
peptide. 
